-
1
-
-
4243776849
-
Mechanisms of adverse drug reactions
-
Davies DM, editor. Textbook of Adverse Drug Reactions. Oxford: Oxford University Press; 1991
-
RawlinsMD, Thompson TJ.Mechanisms of adverse drug reactions. In: Davies DM, editor. Textbook of Adverse Drug Reactions. Oxford: Oxford University Press; 1991.
-
-
-
Rawlins, M.D.1
Thompson, T.J.2
-
2
-
-
15944372781
-
Clarification of terminology in drug safety
-
Aronson JK, Ferner RE. Clarification of terminology in drug safety. Drug Saf 2005; 28(10): 851-70.
-
(2005)
Drug Saf
, vol.28
, Issue.10
, pp. 851-870
-
-
Aronson, J.K.1
Ferner, R.E.2
-
3
-
-
0034106949
-
Risk factors for the development of adverse drug events in hospitalized patients
-
van den Bemt PM, Egberts AC, Lenderink AW, Verzijl JM, Simons KA, van der Pol WS, Leufkens HG. Risk factors for the development of adverse drug events in hospitalized patients. PharmWorld Sci 2000; 22(2): 62-6.
-
(2000)
PharmWorld Sci
, vol.22
, Issue.2
, pp. 62-66
-
-
van den Bemt, P.M.1
Egberts, A.C.2
Lenderink, A.W.3
Verzijl, J.M.4
Simons, K.A.5
van der Pol, W.S.6
Leufkens, H.G.7
-
4
-
-
0033569516
-
Pharmacogenomics: translating functional genomics into rational therapeutics
-
EvansWE, RellingMV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999; 286(5439): 487-91.
-
(1999)
Science
, vol.286
, Issue.5439
, pp. 487-491
-
-
Evans, W.E.1
Relling, M.V.2
-
5
-
-
84965327618
-
An epitome of current medical literature
-
Anonymous.
-
Anonymous. An epitome of current medical literature. Fabism. Br Med J 1894; 2: E77.
-
(1894)
Fabism. Br Med J
, vol.2
-
-
-
6
-
-
0000616920
-
Enzymatic deficiency in primaquine-sensitive erythrocytes
-
Alving AS, Carson PE, Flanagan CL, Ickes CE. Enzymatic deficiency in primaquine-sensitive erythrocytes. Science 1956; 124(3220): 484-5.
-
(1956)
Science
, vol.124
, Issue.3220
, pp. 484-485
-
-
Alving, A.S.1
Carson, P.E.2
Flanagan, C.L.3
Ickes, C.E.4
-
7
-
-
0014483527
-
Drug-induced hemolytic anemia
-
Beutler E. Drug-induced hemolytic anemia. Pharmacol Rev 1969; 21(1): 73-103.
-
(1969)
Pharmacol Rev
, vol.21
, Issue.1
, pp. 73-103
-
-
Beutler, E.1
-
9
-
-
84965047512
-
The relation between dose of succinylcholine and duration of apnea in man
-
Kalow W, Gunn DR. The relation between dose of succinylcholine and duration of apnea in man. J Pharmacol Exp Ther 1957; 120(2): 203-14.
-
(1957)
J Pharmacol Exp Ther
, vol.120
, Issue.2
, pp. 203-214
-
-
Kalow, W.1
Gunn, D.R.2
-
10
-
-
0014426144
-
Untersuchungen zum Polymorphismus der Acetylierung von Isonicotinsaurehydrazid (INH) [Investigations into the polymorphism of acetylation of isonicotinic acid hydrazid (INH)
-
Goedde HW, Schloot W. Untersuchungen zum Polymorphismus der Acetylierung von Isonicotinsaurehydrazid (INH) [Investigations into the polymorphism of acetylation of isonicotinic acid hydrazid (INH).] Med Welt 1968; 51: 2812-21.
-
(1968)
Med Welt
, vol.51
, pp. 2812-2821
-
-
Goedde, H.W.1
Schloot, W.2
-
11
-
-
0017695082
-
Polymorphic hydroxylation of debrisoquine in man
-
Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL. Polymorphic hydroxylation of debrisoquine in man. Lancet 1977; 2(8038): 584-6.
-
(1977)
Lancet
, vol.2
, Issue.8038
, pp. 584-586
-
-
Mahgoub, A.1
Idle, J.R.2
Dring, L.G.3
Lancaster, R.4
Smith, R.L.5
-
12
-
-
0018615011
-
Defective N-oxidation of sparteine in man: a new pharmacogenetic defect
-
Eichelbaum M, Spannbrucker N, Steincke B, Dengler HJ. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol 1979; 16(3): 183-7.
-
(1979)
Eur J Clin Pharmacol
, vol.16
, Issue.3
, pp. 183-187
-
-
Eichelbaum, M.1
Spannbrucker, N.2
Steincke, B.3
Dengler, H.J.4
-
13
-
-
0023854270
-
Characterization of the common genetic defect in humans deficient in debrisoquine metabolism
-
Gonzalez FJ, Skoda RC, Kimura S, UmenoM, Zanger UM, Nebert DW, Gelboin HV, Hardwick JP, Meyer UA. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature 1988; 331(6155): 442-6.
-
(1988)
Nature
, vol.331
, Issue.6155
, pp. 442-446
-
-
Gonzalez, F.J.1
Skoda, R.C.2
Kimura, S.3
Umeno, M.4
Zanger, U.M.5
Nebert, D.W.6
Gelboin, H.V.7
Hardwick, J.P.8
Meyer, U.A.9
-
14
-
-
2042437650
-
International Human Genome Sequencing Consortium
-
International Human Genome Sequencing Consortium. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, et al; Initial sequencing and analysis of the human genome. Nature 2001; 409(6822): 860-921.
-
(2001)
Initial sequencing and analysis of the human genome. Nature
, vol.409
, Issue.6822
, pp. 860-921
-
-
Lander, E.S.1
Linton, L.M.2
Birren, B.3
Nusbaum, C.4
Zody, M.C.5
Baldwin, J.6
-
15
-
-
1542563409
-
Mouse Genome Sequencing Consortium
-
Mouse Genome Sequencing Consortium.Waterston RH, Lindblad-Toh K, Birney E, Rogers J, Abril JF, Agarwal P, et al; Initial sequencing and comparative analysis of the mouse genome. Nature 2002; 420(6915): 520-62.
-
(2002)
Initial sequencing and comparative analysis of the mouse genome. Nature
, vol.420
, Issue.6915
, pp. 520-562
-
-
Waterston, R.H.1
Lindblad-Toh, K.2
Birney, E.3
Rogers, J.4
Abril, J.F.5
Agarwal, P.6
-
16
-
-
79959503826
-
The International HapMap Project
-
The International HapMap Project. Nature 2003; 426(6968): 789-96.
-
(2003)
Nature
, vol.426
, Issue.6968
, pp. 789-796
-
-
-
17
-
-
35348983887
-
A second generation human haplotype map of over 3
-
International HapMap Consortium. Frazer KA, Ballinger DG, Cox DR, Hinds DA, Stuve LL, Gibbs RA, et al; A second generation human haplotype map of over 3.1 million SNPs. Nature 2007; 449(7164): 851-61.
-
(2007)
million SNPs. Nature International HapMap Consortium.
, vol.449
, Issue.7164
, pp. 851-861
-
-
Frazer, K.A.1
Ballinger, D.G.2
Cox, D.R.3
Hinds, D.A.4
Stuve, L.L.5
Gibbs, R.A.6
-
18
-
-
0031226574
-
Genset-Abbott deal heralds pharmacogenomics era
-
Marshall A. Genset-Abbott deal heralds pharmacogenomics era. Nat Biotechnol 1997; 15(9): 829-30.
-
(1997)
Nat Biotechnol
, vol.15
, Issue.9
, pp. 829-830
-
-
Marshall, A.1
-
19
-
-
0030690262
-
Getting the right drug into the right patient
-
Marshall A. Getting the right drug into the right patient. Nat Biotechnol 1997; 15(12): 1249-52.
-
(1997)
Nat Biotechnol
, vol.15
, Issue.12
, pp. 1249-1252
-
-
Marshall, A.1
-
20
-
-
0037068964
-
Clinical importance of the cytochromes P450
-
Nebert DW, Russell DW. Clinical importance of the cytochromes P450. Lancet 2002; 360(9340): 1155-62.
-
(2002)
Lancet
, vol.360
, Issue.9340
, pp. 1155-1162
-
-
Nebert, D.W.1
Russell, D.W.2
-
21
-
-
70149110672
-
Polymorphism of human cytochrome P450 enzymes and its clinical impact
-
Zhou SF, Liu JP, Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev 2009; 41(2): 89-295.
-
(2009)
Drug Metab Rev
, vol.41
, Issue.2
, pp. 89-295
-
-
Zhou, S.F.1
Liu, J.P.2
Chowbay, B.3
-
22
-
-
33645809139
-
The human intestinal cytochrome P450 "pie"
-
Paine MF, Hart HL, Ludington SS, Haining RL, Rettie AE, Zeldin DC. The human intestinal cytochrome P450 "pie". Drug Metab Dispos 2006; 34(5): 880-6.
-
(2006)
Drug Metab Dispos
, vol.34
, Issue.5
, pp. 880-886
-
-
Paine, M.F.1
Hart, H.L.2
Ludington, S.S.3
Haining, R.L.4
Rettie, A.E.5
Zeldin, D.C.6
-
23
-
-
0032793249
-
Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment
-
Ingelman-Sundberg M, Oscarson M, McLellan RA. Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends Pharmacol Sci 1999; 20(8): 342-9.
-
(1999)
Trends Pharmacol Sci
, vol.20
, Issue.8
, pp. 342-349
-
-
Ingelman-Sundberg, M.1
Oscarson, M.2
McLellan, R.A.3
-
24
-
-
0028237729
-
Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians
-
Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994; 270(1): 414-23.
-
(1994)
J Pharmacol Exp Ther
, vol.270
, Issue.1
, pp. 414-423
-
-
Shimada, T.1
Yamazaki, H.2
Mimura, M.3
Inui, Y.4
Guengerich, F.P.5
-
25
-
-
36148976077
-
Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects
-
Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 2007; 116(3): 496-526.
-
(2007)
Pharmacol Ther
, vol.116
, Issue.3
, pp. 496-526
-
-
Ingelman-Sundberg, M.1
Sim, S.C.2
Gomez, A.3
Rodriguez-Antona, C.4
-
26
-
-
44349105538
-
Human Cytochrome P450 (CYP) Allele Nomenclature Committee
-
Home Page
-
Human Cytochrome P450 (CYP) Allele Nomenclature Committee. Home Page. http://www.imm.ki.se/CYPalleles.
-
-
-
-
27
-
-
0029564238
-
Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy
-
Furuya H, Fernandez-Salguero P, GregoryW, Taber H, Steward A, Gonzalez FJ, Idle JR. Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. Pharmacogenetics 1995; 5(6): 389-92.
-
(1995)
Pharmacogenetics
, vol.5
, Issue.6
, pp. 389-392
-
-
Furuya, H.1
Fernandez-Salguero, P.2
Gregory, W.3
Taber, H.4
Steward, A.5
Gonzalez, F.J.6
Idle, J.R.7
-
28
-
-
0033608466
-
Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
-
Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999; 353(9154): 717-9.
-
(1999)
Lancet
, vol.353
, Issue.9154
, pp. 717-719
-
-
Aithal, G.P.1
Day, C.P.2
Kesteven, P.J.3
Daly, A.K.4
-
29
-
-
29244482237
-
Effect of genetic polymorphisms in cytochrome P450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance
-
Kirchheiner J, Roots I, Goldammer M, Rosenkranz B, Brockmoller J. Effect of genetic polymorphisms in cytochrome P450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. Clin Pharmacokinet 2005; 44(12): 1209-25.
-
(2005)
Clin Pharmacokinet
, vol.44
, Issue.12
, pp. 1209-1225
-
-
Kirchheiner, J.1
Roots, I.2
Goldammer, M.3
Rosenkranz, B.4
Brockmoller, J.5
-
30
-
-
0034748878
-
Severe phenytoin intoxication in a subject homozygous for CYP2C9*3
-
BrandoleseR, ScordoMG, SpinaE, Gusella M, PadriniR. Severe phenytoin intoxication in a subject homozygous for CYP2C9*3. Clin Pharmacol Ther 2001; 70(4): 391-4.
-
(2001)
Clin Pharmacol Ther
, vol.70
, Issue.4
, pp. 391-394
-
-
Brandolese, R.1
Scordo, M.G.2
Spina, E.3
Gusella, M.4
Padrini, R.5
-
31
-
-
78149470864
-
Polymorphisms of human cytochrome P450 2C9 and the functional relevance
-
Zhou SF, Zhou ZW, Huang M. Polymorphisms of human cytochrome P450 2C9 and the functional relevance. Toxicology 2010; 278(2): 165-88.
-
(2010)
Toxicology
, vol.278
, Issue.2
, pp. 165-188
-
-
Zhou, S.F.1
Zhou, Z.W.2
Huang, M.3
-
32
-
-
0034638766
-
Pharmacogenetics and adverse drug reactions
-
Meyer UA. Pharmacogenetics and adverse drug reactions. Lancet 2000; 356(9242): 1667-71.
-
(2000)
Lancet
, vol.356
, Issue.9242
, pp. 1667-1671
-
-
Meyer, U.A.1
-
33
-
-
0029622428
-
The pharmacogenetics of codeine hypoalgesia
-
Sindrup SH, Brosen K. The pharmacogenetics of codeine hypoalgesia. Pharmacogenetics 1995; 5(6): 335-46.
-
(1995)
Pharmacogenetics
, vol.5
, Issue.6
, pp. 335-346
-
-
Sindrup, S.H.1
Brosen, K.2
-
34
-
-
0142188770
-
Correlation of CYP2D6 genotype with perhexiline phenotypic metabolizer status
-
Barclay ML, Sawyers SM, Begg EJ, Zhang M, Roberts RL, Kennedy MA, Elliott JM. Correlation of CYP2D6 genotype with perhexiline phenotypic metabolizer status. Pharmacogenetics 2003; 13(10): 627-32.
-
(2003)
Pharmacogenetics
, vol.13
, Issue.10
, pp. 627-632
-
-
Barclay, M.L.1
Sawyers, S.M.2
Begg, E.J.3
Zhang, M.4
Roberts, R.L.5
Kennedy, M.A.6
Elliott, J.M.7
-
35
-
-
13544259943
-
Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: I
-
Tiwari AK, Deshpande SN, Rao AR, Bhatia T, Mukit SR, Shriharsh V, Lerer B, Nimagaonkar VL, Thelma BK. Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: I. Association of CYP1A2 gene polymorphism. Pharmacogenomics J 2005; 5(1): 60-9.
-
(2005)
Association of CYP1A2 gene polymorphism. Pharmacogenomics J
, vol.5
, Issue.1
, pp. 60-69
-
-
Tiwari, A.K.1
Deshpande, S.N.2
Rao, A.R.3
Bhatia, T.4
Mukit, S.R.5
Shriharsh, V.6
Lerer, B.7
Nimagaonkar, V.L.8
Thelma, B.K.9
-
36
-
-
9144230034
-
Six novel nonsynonymous CYP1A2 gene polymorphisms: catalytic activities of the naturally occurring variant enzymes
-
Murayama N, Soyama A, Saito Y, Nakajima Y, Komamura K, Ueno K, Kamakura S, Kitakaze M, Kimura H, Goto Y, SaitohO, KatohM, Ohnuma T, Kawai M, SugaiK, Ohtsuki T, Suzuki C, Minami N, Ozawa S, Sawada J. Six novel nonsynonymous CYP1A2 gene polymorphisms: catalytic activities of the naturally occurring variant enzymes. J Pharmacol Exp Ther 2004; 308(1): 300-6.
-
(2004)
J Pharmacol Exp Ther
, vol.308
, Issue.1
, pp. 300-306
-
-
Murayama, N.1
Soyama, A.2
Saito, Y.3
Nakajima, Y.4
Komamura, K.5
Ueno, K.6
Kamakura, S.7
Kitakaze, M.8
Kimura, H.9
Goto, Y.10
Saitoh, O.11
Katoh, M.12
Ohnuma, T.13
Kawai, M.14
Sugai, K.15
Ohtsuki, T.16
Suzuki, C.17
Minami, N.18
Ozawa, S.19
Sawada, J.20
more..
-
37
-
-
50849104253
-
Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patients
-
Bohanec Grabar P, Rozman B, Tomsic M, Suput D, Logar D, Dolzan V. Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patients. Eur J Clin Pharmacol 2008; 64(9): 871-6.
-
(2008)
Eur J Clin Pharmacol
, vol.64
, Issue.9
, pp. 871-876
-
-
Bohanec Grabar, P.1
Rozman, B.2
Tomsic, M.3
Suput, D.4
Logar, D.5
Dolzan, V.6
-
38
-
-
0035875828
-
Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients
-
Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 2001; 15(1): 71-5.
-
(2001)
AIDS
, vol.15
, Issue.1
, pp. 71-75
-
-
Marzolini, C.1
Telenti, A.2
Decosterd, L.A.3
Greub, G.4
Biollaz, J.5
Buclin, T.6
-
39
-
-
19944428456
-
Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study
-
Haas DW, Ribaudo HJ, Kim RB, Tierney C, Wilkinson GR, Gulick RM, Clifford DB, Hulgan T, Marzolini C, Acosta EP. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS 2004; 18(18): 2391-400.
-
(2004)
AIDS
, vol.18
, Issue.18
, pp. 2391-2400
-
-
Haas, D.W.1
Ribaudo, H.J.2
Kim, R.B.3
Tierney, C.4
Wilkinson, G.R.5
Gulick, R.M.6
Clifford, D.B.7
Hulgan, T.8
Marzolini, C.9
Acosta, E.P.10
-
40
-
-
28844431530
-
CYP2C 19 genotype affects diazepam pharmacokinetics and emergence from general anesthesia
-
Inomata S, Nagashima A, Itagaki F, Homma M, Nishimura M, Osaka Y, Okuyama K, Tanaka E, Nakamura T, Kohda Y, Naito S, Miyabe M, Toyooka H. CYP2C 19 genotype affects diazepam pharmacokinetics and emergence from general anesthesia. Clin Pharmacol Ther 2005; 78(6): 647-55.
-
(2005)
Clin Pharmacol Ther
, vol.78
, Issue.6
, pp. 647-655
-
-
Inomata, S.1
Nagashima, A.2
Itagaki, F.3
Homma, M.4
Nishimura, M.5
Osaka, Y.6
Okuyama, K.7
Tanaka, E.8
Nakamura, T.9
Kohda, Y.10
Naito, S.11
Miyabe, M.12
Toyooka, H.13
-
41
-
-
0034967764
-
Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions
-
Wysowski DK, Corken A, Gallo-Torres H, Talarico L, Rodriguez EM. Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions. Am J Gastroenterol 2001; 96(6): 1698-703.
-
(2001)
Am J Gastroenterol
, vol.96
, Issue.6
, pp. 1698-1703
-
-
Wysowski, D.K.1
Corken, A.2
Gallo-Torres, H.3
Talarico, L.4
Rodriguez, E.M.5
-
42
-
-
0032815783
-
Comparison of CYP2D6 content and metoprolol oxidation between microsomes isolated from human livers and small intestines
-
Madani S, Paine MF, Lewis L, Thummel KE, Shen DD. Comparison of CYP2D6 content and metoprolol oxidation between microsomes isolated from human livers and small intestines. Pharm Res 1999; 16(8): 1199-205.
-
(1999)
Pharm Res
, vol.16
, Issue.8
, pp. 1199-1205
-
-
Madani, S.1
Paine, M.F.2
Lewis, L.3
Thummel, K.E.4
Shen, D.D.5
-
44
-
-
33748787999
-
Pharmacogenetics, drug-metabolizing enzymes, and clinical practice
-
Sep
-
Gardiner SJ, Begg EJ. Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacol Rev 2006 Sep; 58(3): 521-90.
-
(2006)
Pharmacol Rev
, vol.58
, Issue.3
, pp. 521-590
-
-
Gardiner, S.J.1
Begg, E.J.2
-
45
-
-
13544249943
-
Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity
-
Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 2005; 5(1): 6-13.
-
(2005)
Pharmacogenomics J
, vol.5
, Issue.1
, pp. 6-13
-
-
Ingelman-Sundberg, M.1
-
46
-
-
37349057480
-
Review of evidence for genetic testing for CYP450 polymorphisms in management of patients with nonpsychotic depression with selective serotonin reuptake inhibitors
-
Thakur M, Grossman I, McCrory DC, Orlando LA, Steffens DC, Cline KE, Gray RN, Farmer J, DeJesus G, O'Brien C, Samsa G, Goldstein DB, Matchar DB. Review of evidence for genetic testing for CYP450 polymorphisms in management of patients with nonpsychotic depression with selective serotonin reuptake inhibitors. Genet Med 2007; 9(12): 826-35.
-
(2007)
Genet Med
, vol.9
, Issue.12
, pp. 826-835
-
-
Thakur, M.1
Grossman, I.2
McCrory, D.C.3
Orlando, L.A.4
Steffens, D.C.5
Cline, K.E.6
Gray, R.N.7
Farmer, J.8
DeJesus, G.9
O'Brien, C.10
Samsa, G.11
Goldstein, D.B.12
Matchar, D.B.13
-
47
-
-
34547644659
-
Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication
-
Kirchheiner J, SchmidtH, Tzvetkov M, Keulen JT, Lötsch J, Roots I, Brockmöller J. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J 2007; 7(4): 257-65.
-
(2007)
Pharmacogenomics J
, vol.7
, Issue.4
, pp. 257-265
-
-
Kirchheiner, J.1
Schmidt, H.2
Tzvetkov, M.3
Keulen, J.T.4
Lötsch, J.5
Roots, I.6
Brockmöller, J.7
-
48
-
-
35549000170
-
The pharmacogenetics of analgesia
-
Stamer UM, Stuber F. The pharmacogenetics of analgesia. Expert Opin Pharmacother 2007; 8(14): 2235-45.
-
(2007)
Expert Opin Pharmacother
, vol.8
, Issue.14
, pp. 2235-2245
-
-
Stamer, U.M.1
Stuber, F.2
-
49
-
-
33846465345
-
Safety of codeine during breastfeeding: fatal morphine poisoning in the breastfed neonate of a mother prescribed codeine
-
Madadi P, Koren G, Cairns J, Chitayat D, Gaedigk A, Leeder JS, Teitelbaum R, Karaskov T, Aleksa K. Safety of codeine during breastfeeding: fatal morphine poisoning in the breastfed neonate of a mother prescribed codeine. Can Fam Physician 2007; 53(1): 33-5.
-
(2007)
Can Fam Physician
, vol.53
, Issue.1
, pp. 33-35
-
-
Madadi, P.1
Koren, G.2
Cairns, J.3
Chitayat, D.4
Gaedigk, A.5
Leeder, J.S.6
Teitelbaum, R.7
Karaskov, T.8
Aleksa, K.9
-
50
-
-
69049096090
-
ultrarapid-metabolism genotype, and postoperative death
-
Ciszkowski C, Madadi P, Phillips MS, Lauwers AE, Koren G. Codeine, ultrarapid-metabolism genotype, and postoperative death. N Engl J Med 2009; 361(8): 827-8.
-
(2009)
N Engl J Med
, vol.361
, Issue.8
, pp. 827-828
-
-
Ciszkowski, C.1
Madadi, P.2
Phillips, M.S.3
Lauwers, A.E.4
Codeine, K.G.5
-
51
-
-
57749180179
-
Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control study
-
Madadi P, Ross CJ, Hayden MR, Carleton BC, Gaedigk A, Leeder JS, Koren G. Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control study. Clin Pharmacol Ther 2009; 85(1): 31-5.
-
(2009)
Clin Pharmacol Ther
, vol.85
, Issue.1
, pp. 31-35
-
-
Madadi, P.1
Ross, C.J.2
Hayden, M.R.3
Carleton, B.C.4
Gaedigk, A.5
Leeder, J.S.6
Koren, G.7
-
52
-
-
0018865960
-
Perhexilinemaleateassociated hepatic injury prevalence and characteristics
-
Poupon R, Rosensztajn L, Prudhommede Saint-Maur P, Lageron A, Gombeau T, Darnis F. Perhexilinemaleateassociated hepatic injury prevalence and characteristics. Digestion 1980; 20(3): 145-50.
-
(1980)
Digestion
, vol.20
, Issue.3
, pp. 145-150
-
-
Poupon, R.1
Rosensztajn, L.2
Prudhomme de Saint-Maur, P.3
Lageron, A.4
Gombeau, T.5
Darnis, F.6
-
53
-
-
33749027737
-
Can pharmacogenetics help rescue drugs withdrawn from the market?
-
Shah RR. Can pharmacogenetics help rescue drugs withdrawn from the market? Pharmacogenomics 2006; 7(6): 889-908.
-
(2006)
Pharmacogenomics
, vol.7
, Issue.6
, pp. 889-908
-
-
Shah, R.R.1
-
54
-
-
0036263813
-
Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data
-
Lee CR, Goldstein JA, Pieper JA. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 2002; 12(3): 251-63.
-
(2002)
Pharmacogenetics
, vol.12
, Issue.3
, pp. 251-263
-
-
Lee, C.R.1
Goldstein, J.A.2
Pieper, J.A.3
-
55
-
-
77951898626
-
Pharmacogenetics of warfarin
-
Kamali F, Wynne H. Pharmacogenetics of warfarin. Annu Rev Med 2010; 61: 63-75.
-
(2010)
Annu Rev Med
, vol.61
, pp. 63-75
-
-
Kamali, F.1
Wynne, H.2
-
57
-
-
34147162376
-
Pharmacogenetics of warfarin: current status and future challenges
-
Wadelius M, Pirmohamed M. Pharmacogenetics of warfarin: current status and future challenges. Pharmacogenomics J 2007; 7(2): 99-111.
-
(2007)
Pharmacogenomics J
, vol.7
, Issue.2
, pp. 99-111
-
-
Wadelius, M.1
Pirmohamed, M.2
-
58
-
-
23644451632
-
Major bleeding complications in a specialized anticoagulation service
-
Fanikos J, Grasso-Correnti N, Shah R, Kucher N, Goldhaber SZ. Major bleeding complications in a specialized anticoagulation service. Am J Cardiol 2005; 96(4): 595-8.
-
(2005)
Am J Cardiol
, vol.96
, Issue.4
, pp. 595-598
-
-
Fanikos, J.1
Grasso-Correnti, N.2
Shah, R.3
Kucher, N.4
Goldhaber, S.Z.5
-
59
-
-
0033884635
-
Cytochrome P450 polymorphisms are associated with reduced warfarin dose
-
Freeman BD, Zehnbauer BA, McGrath S, Borecki I, Buchman TG. Cytochrome P450 polymorphisms are associated with reduced warfarin dose. Surgery 2000; 128(2): 281-5.
-
(2000)
Surgery
, vol.128
, Issue.2
, pp. 281-285
-
-
Freeman, B.D.1
Zehnbauer, B.A.2
McGrath, S.3
Borecki, I.4
Buchman, T.G.5
-
60
-
-
0037012465
-
Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy
-
HigashiMK, Veenstra DL, Kondo LM, Wittkowsky AK, Srinouanprachanh SL, Farin FM, Rettie AE.Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002; 287(13): 1690-8.
-
(2002)
JAMA
, vol.287
, Issue.13
, pp. 1690-1698
-
-
Higashi, M.K.1
Veenstra, D.L.2
Kondo, L.M.3
Wittkowsky, A.K.4
Srinouanprachanh, S.L.5
Farin, F.M.6
Rettie, A.E.7
-
61
-
-
0033694203
-
Genetic modulation of oral anticoagulation with warfarin
-
Margaglione M, Colaizzo D, D'Andrea G, Brancaccio V, Ciampa A, Grandone E, Di Minno G. Genetic modulation of oral anticoagulation with warfarin. Thromb Haemost 2000; 84(5): 775-8.
-
(2000)
Thromb Haemost
, vol.84
, Issue.5
, pp. 775-778
-
-
Margaglione, M.1
Colaizzo, D.2
D'Andrea, G.3
Brancaccio, V.4
Ciampa, A.5
Grandone, E.6
Di Minno, G.7
-
62
-
-
62549143945
-
Influence of CYP2C9 genotype on warfarin dose requirements-a systematic review and meta-analysis
-
Lindh JD, Holm L, Andersson ML, Rane A. Influence of CYP2C9 genotype on warfarin dose requirements-a systematic review and meta-analysis. Eur J Clin Pharmacol 2009; 65(4): 365-75.
-
(2009)
Eur J Clin Pharmacol
, vol.65
, Issue.4
, pp. 365-375
-
-
Lindh, J.D.1
Holm, L.2
Andersson, M.L.3
Rane, A.4
-
63
-
-
11244332058
-
A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin
-
D'Andrea G, D'Ambrosio RL, Di Perna P, Chetta M, Santacroce R, Brancaccio V, Grandone E, Margaglione M. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 2005; 105(2): 645-9.
-
(2005)
Blood
, vol.105
, Issue.2
, pp. 645-649
-
-
D'Andrea, G.1
D'Ambrosio, R.L.2
Di Perna, P.3
Chetta, M.4
Santacroce, R.5
Brancaccio, V.6
Grandone, E.7
Margaglione, M.8
-
64
-
-
12344331747
-
Pharmacodynamic resistance to warfarin associated with a Val66Met substitution in vitamin K epoxide reductase complex subunit 1
-
Harrington DJ, Underwood S, Morse C, Shearer MJ, Tuddenham EG, Mumford AD. Pharmacodynamic resistance to warfarin associated with a Val66Met substitution in vitamin K epoxide reductase complex subunit 1. Thromb Haemost 2005; 93(1): 23-6.
-
(2005)
Thromb Haemost
, vol.93
, Issue.1
, pp. 23-26
-
-
Harrington, D.J.1
Underwood, S.2
Morse, C.3
Shearer, M.J.4
Tuddenham, E.G.5
Mumford, A.D.6
-
65
-
-
10744228888
-
Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2
-
Rost S, Fregin A, Ivaskevicius V, Conzelmann E, Hortnagel K, Pelz HJ, Lappegard K, Seifried E, Scharrer I, Tuddenham EG, Müller CR, Strom TM, Oldenburg J. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 2004; 427(6974): 537-41.
-
(2004)
Nature
, vol.427
, Issue.6974
, pp. 537-541
-
-
Rost, S.1
Fregin, A.2
Ivaskevicius, V.3
Conzelmann, E.4
Hortnagel, K.5
Pelz, H.J.6
Lappegard, K.7
Seifried, E.8
Scharrer, I.9
Tuddenham, E.G.10
Müller, C.R.11
Strom, T.M.12
Oldenburg, J.13
-
66
-
-
42149188553
-
CYP4F2 genetic variant alters required warfarin dose
-
Caldwell MD, Awad T, Johnson JA, Gage BF, Falkowski M, Gardina P, Hubbard J, Turpaz Y, Langaee TY, Eby C, King CR, Brower A, Schmelzer JR, Glurich I, Vidaillet HJ, Yale SH, Qi Zhang K, Berg RL, Burmester JK. CYP4F2 genetic variant alters required warfarin dose. Blood 2008; 111(8): 4106-12.
-
(2008)
Blood
, vol.111
, Issue.8
, pp. 4106-4112
-
-
Caldwell, M.D.1
Awad, T.2
Johnson, J.A.3
Gage, B.F.4
Falkowski, M.5
Gardina, P.6
Hubbard, J.7
Turpaz, Y.8
Langaee, T.Y.9
Eby, C.10
King, C.R.11
Brower, A.12
Schmelzer, J.R.13
Glurich, I.14
Vidaillet, H.J.15
Yale, S.H.16
Qi Zhang, K.17
Berg, R.L.18
Burmester, J.K.19
-
67
-
-
18844444813
-
Patients with unstable control have a poorer dietary intake of vitamin K compared to patients with stable control of anticoagulation
-
Sconce E, Khan T, Mason J, Noble F, Wynne H, Kamali F. Patients with unstable control have a poorer dietary intake of vitamin K compared to patients with stable control of anticoagulation. Thromb Haemost 2005; 93(5): 872-5.
-
(2005)
Thromb Haemost
, vol.93
, Issue.5
, pp. 872-875
-
-
Sconce, E.1
Khan, T.2
Mason, J.3
Noble, F.4
Wynne, H.5
Kamali, F.6
-
68
-
-
1542346414
-
Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin
-
Kamali F, Khan TI, King BP, Frearson R, Kesteven P, Wood P, Daly AK, Wynne H. Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin. Clin Pharmacol Ther 2004; 75(3): 204-12.
-
(2004)
Clin Pharmacol Ther
, vol.75
, Issue.3
, pp. 204-212
-
-
Kamali, F.1
Khan, T.I.2
King, B.P.3
Frearson, R.4
Kesteven, P.5
Wood, P.6
Daly, A.K.7
Wynne, H.8
-
69
-
-
23044440450
-
The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen
-
Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP, Wood P, Kesteven P, Daly AK, Kamali F. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 2005; 106(7): 2329-33.
-
(2005)
Blood
, vol.106
, Issue.7
, pp. 2329-2333
-
-
Sconce, E.A.1
Khan, T.I.2
Wynne, H.A.3
Avery, P.4
Monkhouse, L.5
King, B.P.6
Wood, P.7
Kesteven, P.8
Daly, A.K.9
Kamali, F.10
-
70
-
-
38049181030
-
Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues
-
Gage BF, Lesko LJ. Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues. J Thromb Thrombolysis 2008; 25(1): 45-51.
-
(2008)
J Thromb Thrombolysis
, vol.25
, Issue.1
, pp. 45-51
-
-
Gage, B.F.1
Lesko, L.J.2
-
71
-
-
70649084116
-
Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design
-
van Schie RM, Wadelius MI, Kamali F, Daly AK, Manolopoulos VG, de Boer A, Barallon R, Verhoef TI, Kirchheiner J, Haschke-Becher E, Briz M, Rosendaal FR, Redekop WK, Pirmohamed M, van der Zee AH. Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design. Pharmacogenomics 2009; 10(10): 1687-95.
-
(2009)
Pharmacogenomics
, vol.10
, Issue.10
, pp. 1687-1695
-
-
van Schie, R.M.1
Wadelius, M.I.2
Kamali, F.3
Daly, A.K.4
Manolopoulos, V.G.5
de Boer, A.6
Barallon, R.7
Verhoef, T.I.8
Kirchheiner, J.9
Haschke-Becher, E.10
Briz, M.11
Rosendaal, F.R.12
Redekop, W.K.13
Pirmohamed, M.14
van der Zee, A.H.15
-
72
-
-
0027519429
-
Characterization of cytochrome P-450 2B6 in human liver microsomes
-
Mimura M, Baba T, Yamazaki H, Ohmori S, Inui Y, Gonzalez FJ, Guengerich FP, Shimada T. Characterization of cytochrome P-450 2B6 in human liver microsomes. Drug Metab Dispos 1993; 21(6): 1048-56.
-
(1993)
Drug Metab Dispos
, vol.21
, Issue.6
, pp. 1048-1056
-
-
Mimura, M.1
Baba, T.2
Yamazaki, H.3
Ohmori, S.4
Inui, Y.5
Gonzalez, F.J.6
Guengerich, F.P.7
Shimada, T.8
-
73
-
-
0030739223
-
Human cytochrome P4502B6: interindividual hepatic expression, substrate specificity, and role in procarcinogen activation
-
Code EL, Crespi CL, Penman BW, Gonzalez FJ, Chang TK, Waxman DJ. Human cytochrome P4502B6: interindividual hepatic expression, substrate specificity, and role in procarcinogen activation. Drug Metab Dispos 1997; 25(8): 985-93.
-
(1997)
Drug Metab Dispos
, vol.25
, Issue.8
, pp. 985-993
-
-
Code, E.L.1
Crespi, C.L.2
Penman, B.W.3
Gonzalez, F.J.4
Chang, T.K.5
Waxman, D.J.6
-
74
-
-
10744221053
-
Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression
-
Lamba V, Lamba J, Yasuda K, Strom S, Davila J, Hancock ML, Fackenthal JD, Rogan PK, Ring B, Wrighton SA, Schuetz EG. Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression. J Pharmacol Exp Ther 2003; 307(3): 906-22.
-
(2003)
J Pharmacol Exp Ther
, vol.307
, Issue.3
, pp. 906-922
-
-
Lamba, V.1
Lamba, J.2
Yasuda, K.3
Strom, S.4
Davila, J.5
Hancock, M.L.6
Fackenthal, J.D.7
Rogan, P.K.8
Ring, B.9
Wrighton, S.A.10
Schuetz, E.G.11
-
75
-
-
0034948077
-
Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver
-
Lang T, Klein K, Fischer J, Nussler AK, Neuhaus P, Hofmann U, Eichelbaum M, Schwab M, Zanger UM. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 2001; 11(5): 399-415.
-
(2001)
Pharmacogenetics
, vol.11
, Issue.5
, pp. 399-415
-
-
Lang, T.1
Klein, K.2
Fischer, J.3
Nussler, A.K.4
Neuhaus, P.5
Hofmann, U.6
Eichelbaum, M.7
Schwab, M.8
Zanger, U.M.9
-
76
-
-
23244462148
-
Therapeutic drug monitoring of efavirenz: trough levels cannot be estimated on the basis of earlier plasma determinations
-
Lopez-Cortes LF, Ruiz-Valderas R, Marin-Niebla A, Pascual-Carrasco R, Rodriguez-Diez M, Lucero-Munoz MJ. Therapeutic drug monitoring of efavirenz: trough levels cannot be estimated on the basis of earlier plasma determinations. J Acquir Immune Defic Syndr 2005; 39(5): 551-6.
-
(2005)
J Acquir Immune Defic Syndr
, vol.39
, Issue.5
, pp. 551-556
-
-
Lopez-Cortes, L.F.1
Ruiz-Valderas, R.2
Marin-Niebla, A.3
Pascual-Carrasco, R.4
Rodriguez-Diez, M.5
Lucero-Munoz, M.J.6
-
77
-
-
31044456584
-
Adult AIDS Clinical Trials Group Study
-
Ribaudo HJ, Haas DW, Tierney C, Kim RB, Wilkinson GR, Gulick RM, Clifford DB, Marzolini C, Fletcher CV, Tashima KT, Kuritzkes DR, Acosta EP; Adult AIDS Clinical Trials Group Study. Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study. Clin Infect Dis 2006; 42(3): 401-7.
-
(2006)
Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study. Clin Infect Dis
, vol.42
, Issue.3
, pp. 401-407
-
-
Ribaudo, H.J.1
Haas, D.W.2
Tierney, C.3
Kim, R.B.4
Wilkinson, G.R.5
Gulick, R.M.6
Clifford, D.B.7
Marzolini, C.8
Fletcher, C.V.9
Tashima, K.T.10
Kuritzkes, D.R.11
Acosta, E.P.12
-
78
-
-
20244364148
-
Swiss HIV Cohort Study
-
Rotger M, Colombo S, Furrer H, Bleiber G, Buclin T, Lee BL, Keiser O, Biollaz J, Décosterd L, Telenti A; Swiss HIV Cohort Study. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet Genomics 2005; 15(1): 1-5.
-
(2005)
Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet Genomics
, vol.15
, Issue.1
, pp. 1-5
-
-
Rotger, M.1
Colombo, S.2
Furrer, H.3
Bleiber, G.4
Buclin, T.5
Lee, B.L.6
Keiser, O.7
Biollaz, J.8
Décosterd, L.9
Telenti, A.10
-
79
-
-
35348923463
-
Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26
-
Gatanaga H, Hayashida T, Tsuchiya K, Yoshino M, Kuwahara T, Tsukada H, Fujimoto K, Sato I, Ueda M, Horiba M, Hamaguchi M, Yamamoto M, Takata N, Kimura A, Koike T, Gejyo F, Matsushita S, Shirasaka T, Kimura S, Oka S. Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6*6 and *26. Clin Infect Dis 2007; 45(9): 1230-7.
-
(2007)
Clin Infect Dis
, vol.45
, Issue.9
, pp. 1230-1237
-
-
Gatanaga, H.1
Hayashida, T.2
Tsuchiya, K.3
Yoshino, M.4
Kuwahara, T.5
Tsukada, H.6
Fujimoto, K.7
Sato, I.8
Ueda, M.9
Horiba, M.10
Hamaguchi, M.11
Yamamoto, M.12
Takata, N.13
Kimura, A.14
Koike, T.15
Gejyo, F.16
Matsushita, S.17
Shirasaka, T.18
Kimura, S.19
Oka, S.20
more..
-
80
-
-
0035369825
-
Genetic susceptibility to adverse drug reactions
-
Pirmohamed M, Park BK. Genetic susceptibility to adverse drug reactions. Trends Pharmacol Sci 2001; 22(6): 298-305.
-
(2001)
Trends Pharmacol Sci
, vol.22
, Issue.6
, pp. 298-305
-
-
Pirmohamed, M.1
Park, B.K.2
-
81
-
-
0018822866
-
Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity
-
Weinshilboum RM, Sladek SL.Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980; 32(5): 651-62.
-
(1980)
Am J Hum Genet
, vol.32
, Issue.5
, pp. 651-662
-
-
Weinshilboum, R.M.1
Sladek, S.L.2
-
82
-
-
0025331198
-
Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia
-
Lennard L, Lilleyman JS, Van Loon J, Weinshilboum RM. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 1990; 336(8709): 225-9.
-
(1990)
Lancet
, vol.336
, Issue.8709
, pp. 225-229
-
-
Lennard, L.1
Lilleyman, J.S.2
Van Loon, J.3
Weinshilboum, R.M.4
-
83
-
-
2342459714
-
Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan
-
Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M, Karrison T, Janisch L, Ramírez J, Rudin CM, Vokes EE, Ratain MJ. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004; 22(8): 1382-8.
-
(2004)
J Clin Oncol
, vol.22
, Issue.8
, pp. 1382-1388
-
-
Innocenti, F.1
Undevia, S.D.2
Iyer, L.3
Chen, P.X.4
Das, S.5
Kocherginsky, M.6
Karrison, T.7
Janisch, L.8
Ramírez, J.9
Rudin, C.M.10
Vokes, E.E.11
Ratain, M.J.12
-
84
-
-
0036025450
-
UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity
-
Iyer L, Das S, Janisch L, Wen M, Ramirez J, Karrison T, Fleming GF, Vokes EE, Schilsky RL, Ratain MJ. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2002; 2(1): 43-7.
-
(2002)
Pharmacogenomics J
, vol.2
, Issue.1
, pp. 43-47
-
-
Iyer, L.1
Das, S.2
Janisch, L.3
Wen, M.4
Ramirez, J.5
Karrison, T.6
Fleming, G.F.7
Vokes, E.E.8
Schilsky, R.L.9
Ratain, M.J.10
-
85
-
-
25844446183
-
Swiss HIV Cohort Study
-
Rotger M, Taffe P, Bleiber G, Gunthard HF, Furrer H, Vernazza P, Drechsler H, Bernasconi E, Rickenbach M, Telenti A; Swiss HIV Cohort Study. Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. J Infect Dis 2005; 192(8): 1381-6.
-
(2005)
Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. J Infect Dis
, vol.192
, Issue.8
, pp. 1381-1386
-
-
Rotger, M.1
Taffe, P.2
Bleiber, G.3
Gunthard, H.F.4
Furrer, H.5
Vernazza, P.6
Drechsler, H.7
Bernasconi, E.8
Rickenbach, M.9
Telenti, A.10
-
86
-
-
35648936586
-
UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia
-
Singer JB, Shou Y, Giles F, Kantarjian HM, Hsu Y, Robeva AS, Rae P, Weitzman A, Meyer JM, Dugan M, Ottmann OG. UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia. Leukemia 2007; 21(11): 2311-15.
-
(2007)
Leukemia
, vol.21
, Issue.11
, pp. 2311-2315
-
-
Singer, J.B.1
Shou, Y.2
Giles, F.3
Kantarjian, H.M.4
Hsu, Y.5
Robeva, A.S.6
Rae, P.7
Weitzman, A.8
Meyer, J.M.9
Dugan, M.10
Ottmann, O.G.11
-
87
-
-
18744384091
-
Pharmacogenetic analysis of adverse drug effect reveals genetic variant for susceptibility to liver toxicity
-
Acuna G, Foernzler D, Leong D, Rabbia M, Smit R, Dorflinger E, Gasser R, Hoh J, Ott J, Borroni E, To Z, Thompson A, Li J, Hashimoto L, Lindpaintner K. Pharmacogenetic analysis of adverse drug effect reveals genetic variant for susceptibility to liver toxicity. Pharmacogenomics J 2002; 2(5): 327-34.
-
(2002)
Pharmacogenomics J
, vol.2
, Issue.5
, pp. 327-334
-
-
Acuna, G.1
Foernzler, D.2
Leong, D.3
Rabbia, M.4
Smit, R.5
Dorflinger, E.6
Gasser, R.7
Hoh, J.8
Ott, J.9
Borroni, E.10
To, Z.11
Thompson, A.12
Li, J.13
Hashimoto, L.14
Lindpaintner, K.15
-
88
-
-
0028902661
-
Glutathione S-transferase mu genotype (GSTM1*0) in Alzheimer's patients with tacrine transaminitis
-
Green VJ, Pirmohamed M, Kitteringham NR, Knapp MJ, Park BK. Glutathione S-transferase mu genotype (GSTM1*0) in Alzheimer's patients with tacrine transaminitis. Br J Clin Pharmacol 1995; 39(4): 411-15.
-
(1995)
Br J Clin Pharmacol
, vol.39
, Issue.4
, pp. 411-415
-
-
Green, V.J.1
Pirmohamed, M.2
Kitteringham, N.R.3
Knapp, M.J.4
Park, B.K.5
-
89
-
-
0034112853
-
Combined glutathione-S-transferase M1 and T1 genetic polymorphism and tacrine hepatotoxicity
-
Simon T, Becquemont L, Mary-Krause M, de Waziers I, Beaune P, Funck-Brentano C, Jaillon P. Combined glutathione-S-transferase M1 and T1 genetic polymorphism and tacrine hepatotoxicity. Clin Pharmacol Ther 2000; 67(4): 432-7.
-
(2000)
Clin Pharmacol Ther
, vol.67
, Issue.4
, pp. 432-437
-
-
Simon, T.1
Becquemont, L.2
Mary-Krause, M.3
de Waziers, I.4
Beaune, P.5
Funck-Brentano, C.6
Jaillon, P.7
-
90
-
-
0038708252
-
A study to survey susceptible genetic factors responsible for troglitazone-associated hepatotoxicity in Japanese patients with type 2 diabetes mellitus
-
Watanabe I, Tomita A, Shimizu M, Sugawara M, Yasumo H, Koishi R, Takahashi T, Miyoshi K, Nakamura K, Izumi T, Matsushita Y, Furukawa H, Haruyama H, Koga T. A study to survey susceptible genetic factors responsible for troglitazone-associated hepatotoxicity in Japanese patients with type 2 diabetes mellitus. Clin Pharmacol Ther 2003; 73(5): 435-55.
-
(2003)
Clin Pharmacol Ther
, vol.73
, Issue.5
, pp. 435-455
-
-
Watanabe, I.1
Tomita, A.2
Shimizu, M.3
Sugawara, M.4
Yasumo, H.5
Koishi, R.6
Takahashi, T.7
Miyoshi, K.8
Nakamura, K.9
Izumi, T.10
Matsushita, Y.11
Furukawa, H.12
Haruyama, H.13
Koga, T.14
-
91
-
-
33947590154
-
Cisplatin-induced long-term hearing impairment is associated with specific glutathione s-transferase genotypes in testicular cancer survivors
-
Oldenburg J, Kraggerud SM, CvancarovaM, Lothe RA, Fossa SD. Cisplatin-induced long-term hearing impairment is associated with specific glutathione s-transferase genotypes in testicular cancer survivors. J Clin Oncol 2007; 25(6): 708-14.
-
(2007)
J Clin Oncol
, vol.25
, Issue.6
, pp. 708-714
-
-
Oldenburg, J.1
Kraggerud, S.M.2
Cvancarova, M.3
Lothe, R.A.4
Fossa, S.D.5
-
92
-
-
0036009619
-
The thiopurine S-methyltransferase gene locus-implications for clinical pharmacogenomics
-
McLeod HL, Siva C. The thiopurine S-methyltransferase gene locus-implications for clinical pharmacogenomics. Pharmacogenomics 2002; 3(1): 89-98.
-
(2002)
Pharmacogenomics
, vol.3
, Issue.1
, pp. 89-98
-
-
McLeod, H.L.1
Siva, C.2
-
93
-
-
33645119580
-
Thiopurine S-methyltransferase pharmacogenetics: insights, challenges and future directions
-
Wang L, Weinshilboum R. Thiopurine S-methyltransferase pharmacogenetics: insights, challenges and future directions. Oncogene 2006; 25(11): 1629-38.
-
(2006)
Oncogene
, vol.25
, Issue.11
, pp. 1629-1638
-
-
Wang, L.1
Weinshilboum, R.2
-
94
-
-
54049121096
-
Highly multiplexed genotyping of thiopurine s-methyltransferase variants usingMALD-TOFmass spectrometry: reliable genotyping in different ethnic groups
-
Schaeffeler E, Zanger UM, EichelbaumM, Asante-Poku S, Shin JG, SchwabM. Highly multiplexed genotyping of thiopurine s-methyltransferase variants usingMALD-TOFmass spectrometry: reliable genotyping in different ethnic groups. Clin Chem 2008; 54(10): 1637-47.
-
(2008)
Clin Chem
, vol.54
, Issue.10
, pp. 1637-1647
-
-
Schaeffeler, E.1
Zanger, U.M.2
Eichelbaum, M.3
Asante-Poku, S.4
Shin, J.G.5
Schwab, M.6
-
95
-
-
33745150832
-
Ethnic differences in pharmacogenetically relevant genes
-
Engen RM, Marsh S, Van Booven DJ, McLeod HL. Ethnic differences in pharmacogenetically relevant genes. Curr Drug Targets 2006; 7(12): 1641-8.
-
(2006)
Curr Drug Targets
, vol.7
, Issue.12
, pp. 1641-1648
-
-
Engen, R.M.1
Marsh, S.2
Van Booven, D.J.3
McLeod, H.L.4
-
96
-
-
40049089901
-
Thiopurine S-methyltransferase activity in three major Asian populations: a population-based study in Singapore
-
Kham SK, Soh CK, Liu TC, Chan YH, Ariffin H, Tan PL, Yeoh AE. Thiopurine S-methyltransferase activity in three major Asian populations: a population-based study in Singapore. Eur J Clin Pharmacol 2008; 64(4): 373-9.
-
(2008)
Eur J Clin Pharmacol
, vol.64
, Issue.4
, pp. 373-379
-
-
Kham, S.K.1
Soh, C.K.2
Liu, T.C.3
Chan, Y.H.4
Ariffin, H.5
Tan, P.L.6
Yeoh, A.E.7
-
97
-
-
2542465496
-
Food andDrugAdministration
-
Center forDrugEvaluation and Research.Meeting of the Pediatric Subcommittee of theOncologicDrugs Advisory Committee
-
Food andDrugAdministration. Center forDrugEvaluation and Research.Meeting of the Pediatric Subcommittee of theOncologicDrugs Advisory Committee. http://www.fda.gov/ohrms/dockets/ac/03/transcripts/3971T1.htm.
-
-
-
-
98
-
-
33947357078
-
Current use of pharmacogenetic testing: a national survey of thiopurine methyltransferase testing prior to azathioprine prescription
-
Fargher EA, Tricker K, Newman W, Elliott R, Roberts SA, Shaffer JL, Bruce I, Payne K. Current use of pharmacogenetic testing: a national survey of thiopurine methyltransferase testing prior to azathioprine prescription. J Clin Pharm Ther 2007; 32(2): 187-95.
-
(2007)
J Clin Pharm Ther
, vol.32
, Issue.2
, pp. 187-195
-
-
Fargher, E.A.1
Tricker, K.2
Newman, W.3
Elliott, R.4
Roberts, S.A.5
Shaffer, J.L.6
Bruce, I.7
Payne, K.8
-
99
-
-
0033760290
-
Polymorphisms in UDP glucuronosyltransferase genes: functional consequences and clinical relevance
-
Mackenzie PI, Miners JO, McKinnon RA. Polymorphisms in UDP glucuronosyltransferase genes: functional consequences and clinical relevance. Clin Chem Lab Med 2000; 38(9): 889-92.
-
(2000)
Clin Chem Lab Med
, vol.38
, Issue.9
, pp. 889-892
-
-
Mackenzie, P.I.1
Miners, J.O.2
McKinnon, R.A.3
-
100
-
-
0035884212
-
Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel
-
Rothenberg ML, Meropol NJ, Poplin EA, Van Cutsem E, Wadler S. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 2001; 19(18): 3801-7.
-
(2001)
J Clin Oncol
, vol.19
, Issue.18
, pp. 3801-3807
-
-
Rothenberg, M.L.1
Meropol, N.J.2
Poplin, E.A.3
Van Cutsem, E.4
Wadler, S.5
-
101
-
-
33750583902
-
Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy
-
O'Dwyer PJ, Catalano RB. Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy. J Clin Oncol 2006; 24(28): 4534-8.
-
(2006)
J Clin Oncol
, vol.24
, Issue.28
, pp. 4534-4538
-
-
O'Dwyer, P.J.1
Catalano, R.B.2
-
102
-
-
0028867826
-
Oude Elferink RP, Chowdhury NR
-
Bosma PJ, Chowdhury JR, Bakker C, Gantla S, de Boer A, Oostra BA, Lindhout D, Tytgat GN, Jansen PL, Oude Elferink RP, Chowdhury NR. The genetic basis of the reduced expression of bilirubin UDPglucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med 1995; 333(18): 1171-5.
-
(1995)
The genetic basis of the reduced expression of bilirubin UDPglucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med
, vol.333
, Issue.18
, pp. 1171-1175
-
-
Bosma, P.J.1
Chowdhury, J.R.2
Bakker, C.3
Gantla, S.4
de Boer, A.5
Oostra, B.A.6
Lindhout, D.7
Tytgat, G.N.8
Jansen, P.L.9
-
103
-
-
0034671387
-
Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis
-
Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H, Yokoyama A, Saitoh S, Shimokata K, Hasegawa Y. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 2000; 60(24): 6921-6.
-
(2000)
Cancer Res
, vol.60
, Issue.24
, pp. 6921-6926
-
-
Ando, Y.1
Saka, H.2
Ando, M.3
Sawa, T.4
Muro, K.5
Ueoka, H.6
Yokoyama, A.7
Saitoh, S.8
Shimokata, K.9
Hasegawa, Y.10
-
104
-
-
34250629236
-
UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan
-
Cote JF, Kirzin S, Kramar A, Mosnier JF, Diebold MD, Soubeyran I, Thirouard AS, Selves J, Laurent-Puig P, Ychou M. UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan. Clin Cancer Res 2007; 13(11): 3269-75.
-
(2007)
Clin Cancer Res
, vol.13
, Issue.11
, pp. 3269-3275
-
-
Cote, J.F.1
Kirzin, S.2
Kramar, A.3
Mosnier, J.F.4
Diebold, M.D.5
Soubeyran, I.6
Thirouard, A.S.7
Selves, J.8
Laurent-Puig, P.9
Ychou, M.10
-
105
-
-
73349138231
-
UGT1A1 genotyping: a predictor of irinotecan-associated side effects and drug efficacy?
-
Schulz C, Boeck S, Heinemann V, Stemmler HJ. UGT1A1 genotyping: a predictor of irinotecan-associated side effects and drug efficacy? Anticancer Drugs 2009; 20(10): 867-79.
-
(2009)
Anticancer Drugs
, vol.20
, Issue.10
, pp. 867-879
-
-
Schulz, C.1
Boeck, S.2
Heinemann, V.3
Stemmler, H.J.4
-
106
-
-
34548598459
-
UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters
-
Hoskins JM, Goldberg RM, Qu P, Ibrahim JG, McLeod HL. UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst 2007; 99(17): 1290-5.
-
(2007)
J Natl Cancer Inst
, vol.99
, Issue.17
, pp. 1290-1295
-
-
Hoskins, J.M.1
Goldberg, R.M.2
Qu, P.3
Ibrahim, J.G.4
McLeod, H.L.5
-
107
-
-
24344439264
-
Transporters and drug therapy: implications for drug disposition and disease
-
Ho RH, Kim RB. Transporters and drug therapy: implications for drug disposition and disease. Clin Pharmacol Ther 2005; 78(3): 260-77.
-
(2005)
Clin Pharmacol Ther
, vol.78
, Issue.3
, pp. 260-277
-
-
Ho, R.H.1
Kim, R.B.2
-
108
-
-
70350048926
-
Impact of OATP transporters on pharmacokinetics
-
Kalliokoski A, Niemi M. Impact of OATP transporters on pharmacokinetics. Br J Pharmacol 2009; 158(3): 693-705.
-
(2009)
Br J Pharmacol
, vol.158
, Issue.3
, pp. 693-705
-
-
Kalliokoski, A.1
Niemi, M.2
-
109
-
-
49949104757
-
SLCO1B1 variants and statin-induced myopathy-a genomewide study
-
Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M, Collins R. SLCO1B1 variants and statin-induced myopathy-a genomewide study. N Engl J Med 2008; 359(8): 789-99.
-
(2008)
N Engl J Med
, vol.359
, Issue.8
, pp. 789-799
-
-
Link, E.1
Parish, S.2
Armitage, J.3
Bowman, L.4
Heath, S.5
Matsuda, F.6
Gut, I.7
Lathrop, M.8
Collins, R.9
-
110
-
-
70349739250
-
The SLCO1B1*5 genetic variant is associated with statin-induced side effects
-
Voora D, Shah SH, Spasojevic I, Ali S, Reed CR, Salisbury BA, Ginsburg GS. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol 2009; 54(17): 1609-16.
-
(2009)
J Am Coll Cardiol
, vol.54
, Issue.17
, pp. 1609-1616
-
-
Voora, D.1
Shah, S.H.2
Spasojevic, I.3
Ali, S.4
Reed, C.R.5
Salisbury, B.A.6
Ginsburg, G.S.7
-
111
-
-
73449131555
-
Prolonged neutropenia after irinotecanbased chemotherapy in a child with polymorphisms of UGT1A1 and SLCO1B1
-
Sakaguchi S, Garcia-Bournissen F, Kim R, SchwarzUI, Nathan PC, Ito S. Prolonged neutropenia after irinotecanbased chemotherapy in a child with polymorphisms of UGT1A1 and SLCO1B1. Arch Dis Child 2009; 94(12): 981-2.
-
(2009)
Arch Dis Child
, vol.94
, Issue.12
, pp. 981-982
-
-
Sakaguchi, S.1
Garcia-Bournissen, F.2
Kim, R.3
Schwarz, U.I.4
Nathan, P.C.5
Ito, S.6
-
112
-
-
63949084512
-
Life-threatening toxicities in a patient with UGT1A1*6/*28 and SLCO1B1*15/*15 genotypes after irinotecan-based chemotherapy
-
Takane H, Kawamoto K, Sasaki T, Moriki K, KitanoH, Higuchi S, Otsubo K, Ieiri I. Life-threatening toxicities in a patient with UGT1A1*6/*28 and SLCO1B1*15/*15 genotypes after irinotecan-based chemotherapy. Cancer Chemother Pharmacol 2009; 63(6): 1165-9.
-
(2009)
Cancer Chemother Pharmacol
, vol.63
, Issue.6
, pp. 1165-1169
-
-
Takane, H.1
Kawamoto, K.2
Sasaki, T.3
Moriki, K.4
Kitano, H.5
Higuchi, S.6
Otsubo, K.7
Ieiri, I.8
-
113
-
-
0038106665
-
Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs
-
Sakaeda T, Nakamura T, Okumura K. Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs. Pharmacogenomics 2003; 4(4): 397-410.
-
(2003)
Pharmacogenomics
, vol.4
, Issue.4
, pp. 397-410
-
-
Sakaeda, T.1
Nakamura, T.2
Okumura, K.3
-
114
-
-
33644876141
-
NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity
-
Wojnowski L, Kulle B, Schirmer M, Schluter G, SchmidtA, Rosenberger A, Vonhof S, Bickeböller H, Toliat MR, Suk EK, Tzvetkov M, KrugerA, Seifert S, KloessM, HahnH, Loeffler M, Nürnberg P, Pfreundschuh M, Trümper L, Brockmöller J, Hasenfuss G. NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation 2005; 112(24): 3754-62.
-
(2005)
Circulation
, vol.112
, Issue.24
, pp. 3754-3762
-
-
Wojnowski, L.1
Kulle, B.2
Schirmer, M.3
Schluter, G.4
Schmidt, A.5
Rosenberger, A.6
Vonhof, S.7
Bickeböller, H.8
Toliat, M.R.9
Suk, E.K.10
Tzvetkov, M.11
Kruger, A.12
Seifert, S.13
Kloess, M.14
Hahn, H.15
Loeffler, M.16
Nürnberg, P.17
Pfreundschuh, M.18
Trümper, L.19
Brockmöller, J.20
Hasenfuss, G.21
more..
-
115
-
-
41849115973
-
Methotrexate (MTX) pathway gene polymorphisms and their effects onMTXtoxicity in Caucasian and African American patients with rheumatoid arthritis
-
Apr
-
Ranganathan P, Culverhouse R, Marsh S, Mody A, Scott-Horton TJ, Brasington R, Joseph A, Reddy V, Eisen S, McLeod HL.Methotrexate (MTX) pathway gene polymorphisms and their effects onMTXtoxicity in Caucasian and African American patients with rheumatoid arthritis. J Rheumatol 2008 Apr; 35(4): 572-9.
-
(2008)
J Rheumatol
, vol.35
, Issue.4
, pp. 572-579
-
-
Ranganathan, P.1
Culverhouse, R.2
Marsh, S.3
Mody, A.4
Scott-Horton, T.J.5
Brasington, R.6
Joseph, A.7
Reddy, V.8
Eisen, S.9
McLeod, H.L.10
-
116
-
-
33845226137
-
Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy
-
Izzedine H, Hulot JS, Villard E, Goyenvalle C, Dominguez S, Ghosn J, Valantin MA, Lechat P, Deray AG. Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy. J Infect Dis 2006; 194(11): 1481-91.
-
(2006)
J Infect Dis
, vol.194
, Issue.11
, pp. 1481-1491
-
-
Izzedine, H.1
Hulot, J.S.2
Villard, E.3
Goyenvalle, C.4
Dominguez, S.5
Ghosn, J.6
Valantin, M.A.7
Lechat, P.8
Deray, A.G.9
-
117
-
-
66949119640
-
Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study
-
Rodriguez-Novoa S, Labarga P, Soriano V, Egan D, Albalater M, Morello J, Cuenca L, González-Pardo G, Khoo S, Back D, Owen A. Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. Clin Infect Dis 2009; 48(11): e108-16.
-
(2009)
Clin Infect Dis
, vol.48
, Issue.11
-
-
Rodriguez-Novoa, S.1
Labarga, P.2
Soriano, V.3
Egan, D.4
Albalater, M.5
Morello, J.6
Cuenca, L.7
González-Pardo, G.8
Khoo, S.9
Back, D.10
Owen, A.11
-
118
-
-
33846230114
-
Genetic susceptibility to diclofenacinduced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes
-
Daly AK, Aithal GP, Leathart JB, Swainsbury RA, Dang TS, Day CP. Genetic susceptibility to diclofenacinduced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology 2007; 132(1): 272-81.
-
(2007)
Gastroenterology
, vol.132
, Issue.1
, pp. 272-281
-
-
Daly, A.K.1
Aithal, G.P.2
Leathart, J.B.3
Swainsbury, R.A.4
Dang, T.S.5
Day, C.P.6
-
119
-
-
33845657889
-
Pharmacogenetics of ABCG2 and adverse reactions to gefitinib
-
Cusatis G, Gregorc V, Li J, Spreafico A, Ingersoll RG, Verweij J, Ludovini V, Villa E, Hidalgo M, Sparreboom A, Baker SD. Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J Natl Cancer Inst 2006; 98(23): 1739-42.
-
(2006)
J Natl Cancer Inst
, vol.98
, Issue.23
, pp. 1739-1742
-
-
Cusatis, G.1
Gregorc, V.2
Li, J.3
Spreafico, A.4
Ingersoll, R.G.5
Verweij, J.6
Ludovini, V.7
Villa, E.8
Hidalgo, M.9
Sparreboom, A.10
Baker, S.D.11
-
120
-
-
70350455706
-
Single nucleotide polymorphism in ABCG2 is associated with irinotecaninduced severe myelosuppression
-
Cha PC, Mushiroda T, Zembutsu H, Harada H, Shinoda N, Kawamoto S, Shimoyama R, Nishidate T, Furuhata T, Sasaki K, Hirata K, Nakamura Y. Single nucleotide polymorphism in ABCG2 is associated with irinotecaninduced severe myelosuppression. J Hum Genet 2009; 54(10): 572-80.
-
(2009)
J Hum Genet
, vol.54
, Issue.10
, pp. 572-580
-
-
Cha, P.C.1
Mushiroda, T.2
Zembutsu, H.3
Harada, H.4
Shinoda, N.5
Kawamoto, S.6
Shimoyama, R.7
Nishidate, T.8
Furuhata, T.9
Sasaki, K.10
Hirata, K.11
Nakamura, Y.12
-
122
-
-
2042469487
-
Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics
-
Mwinyi J, Johne A, Bauer S, Roots I, Gerloff T. Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. Clin Pharmacol Ther 2004; 75(5): 415-21.
-
(2004)
Clin Pharmacol Ther
, vol.75
, Issue.5
, pp. 415-421
-
-
Mwinyi, J.1
Johne, A.2
Bauer, S.3
Roots, I.4
Gerloff, T.5
-
123
-
-
3242808852
-
High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1)
-
Niemi M, Schaeffeler E, Lang T, Fromm MF, Neuvonen M, Kyrklund C, Backman JT, Kerb R, Schwab M, Neuvonen PJ, Eichelbaum M, Kivistö KT. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics 2004; 14(7): 429-40.
-
(2004)
Pharmacogenetics
, vol.14
, Issue.7
, pp. 429-440
-
-
Niemi, M.1
Schaeffeler, E.2
Lang, T.3
Fromm, M.F.4
Neuvonen, M.5
Kyrklund, C.6
Backman, J.T.7
Kerb, R.8
Schwab, M.9
Neuvonen, P.J.10
Eichelbaum, M.11
Kivistö, K.T.12
-
124
-
-
42149127614
-
The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15
-
Deng JW, Song IS, Shin HJ, Yeo CW, Cho DY, Shon JH, Shin JG. The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15. Pharmacogenet Genomics 2008; 18(5): 424-33.
-
(2008)
Pharmacogenet Genomics
, vol.18
, Issue.5
, pp. 424-433
-
-
Deng, J.W.1
Song, I.S.2
Shin, H.J.3
Yeo, C.W.4
Cho, D.Y.5
Shon, J.H.6
Shin, J.G.7
-
125
-
-
36148953896
-
Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin
-
Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi M. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 2007; 82(6): 726-33.
-
(2007)
Clin Pharmacol Ther
, vol.82
, Issue.6
, pp. 726-733
-
-
Pasanen, M.K.1
Fredrikson, H.2
Neuvonen, P.J.3
Niemi, M.4
-
126
-
-
33751096467
-
SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid
-
Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics 2006; 16(12): 873-9.
-
(2006)
Pharmacogenet Genomics
, vol.16
, Issue.12
, pp. 873-879
-
-
Pasanen, M.K.1
Neuvonen, M.2
Neuvonen, P.J.3
Niemi, M.4
-
127
-
-
33749049136
-
SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin
-
Niemi M, Pasanen MK, Neuvonen PJ. SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clin Pharmacol Ther 2006; 80(4): 356-66.
-
(2006)
Clin Pharmacol Ther
, vol.80
, Issue.4
, pp. 356-366
-
-
Niemi, M.1
Pasanen, M.K.2
Neuvonen, P.J.3
-
128
-
-
33846568546
-
ABCB1 pharmacogenetics: progress, pitfalls, and promise
-
Chinn LW, Kroetz DL. ABCB1 pharmacogenetics: progress, pitfalls, and promise. Clin Pharmacol Ther 2007; 81(2): 265-9.
-
(2007)
Clin Pharmacol Ther
, vol.81
, Issue.2
, pp. 265-269
-
-
Chinn, L.W.1
Kroetz, D.L.2
-
129
-
-
42949143111
-
Genetic variations and gene expression of transporters in drug disposition and response
-
Huang Y, Penchala S, Pham AN, Wang J. Genetic variations and gene expression of transporters in drug disposition and response. Expert Opin Drug Metab Toxicol 2008; 4(3): 237-54.
-
(2008)
Expert Opin Drug Metab Toxicol
, vol.4
, Issue.3
, pp. 237-254
-
-
Huang, Y.1
Penchala, S.2
Pham, A.N.3
Wang, J.4
-
130
-
-
10744222684
-
Pharmacogenetics of Membrane Transporters Investigators
-
Kroetz DL, Pauli-Magnus C, Hodges LM, Huang CC, Kawamoto M, Johns SJ, Stryke D, Ferrin TE, DeYoung J, Taylor T, Carlson EJ, Herskowitz I, Giacomini KM, Clark AG; Pharmacogenetics of Membrane Transporters Investigators. Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics 2003; 13(8): 481-94.
-
(2003)
Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics
, vol.13
, Issue.8
, pp. 481-494
-
-
Kroetz, D.L.1
Pauli-Magnus, C.2
Hodges, L.M.3
Huang, C.C.4
Kawamoto, M.5
Johns, S.J.6
Stryke, D.7
Ferrin, T.E.8
DeYoung, J.9
Taylor, T.10
Carlson, E.J.11
Herskowitz, I.12
Giacomini, K.M.13
Clark, A.G.14
-
131
-
-
12344334846
-
Clinical aspects of the MDR1 (ABCB1) gene polymorphism
-
Eichelbaum M, Fromm MF, Schwab M. Clinical aspects of the MDR1 (ABCB1) gene polymorphism. Ther Drug Monit 2004; 26(2): 180-5.
-
(2004)
Ther Drug Monit
, vol.26
, Issue.2
, pp. 180-185
-
-
Eichelbaum, M.1
Fromm, M.F.2
Schwab, M.3
-
132
-
-
12444273301
-
MDR1 genotype-related duodenal absorption rate of digoxin in healthy Japanese subjects
-
Morita Y, Sakaeda T, Horinouchi M, Nakamura T, Kuroda K, Miki I, Yoshimura K, Sakai T, Shirasaka D, Tamura T, Aoyama N, Kasuga M, Okumura K. MDR1 genotype-related duodenal absorption rate of digoxin in healthy Japanese subjects. Pharm Res 2003; 20(4): 552-6.
-
(2003)
Pharm Res
, vol.20
, Issue.4
, pp. 552-556
-
-
Morita, Y.1
Sakaeda, T.2
Horinouchi, M.3
Nakamura, T.4
Kuroda, K.5
Miki, I.6
Yoshimura, K.7
Sakai, T.8
Shirasaka, D.9
Tamura, T.10
Aoyama, N.11
Kasuga, M.12
Okumura, K.13
-
133
-
-
23044491475
-
Meta-analysis of the influence of MDR1 C3435T polymorphism on digoxin pharmacokinetics and MDR1 gene expression
-
Chowbay B, Li H, David M, Cheung YB, Lee EJ. Meta-analysis of the influence of MDR1 C3435T polymorphism on digoxin pharmacokinetics and MDR1 gene expression. Br J Clin Pharmacol 2005; 60(2): 159-71.
-
(2005)
Br J Clin Pharmacol
, vol.60
, Issue.2
, pp. 159-171
-
-
Chowbay, B.1
Li, H.2
David, M.3
Cheung, Y.B.4
Lee, E.J.5
-
134
-
-
18144399975
-
Clinical pharmacogenetics of immunosuppressive drugs in organ transplantation
-
Szekeres T, Haushofer A. Clinical pharmacogenetics of immunosuppressive drugs in organ transplantation. Pharmacogenomics 2005; 6(2): 163-8.
-
(2005)
Pharmacogenomics
, vol.6
, Issue.2
, pp. 163-168
-
-
Szekeres, T.1
Haushofer, A.2
-
135
-
-
48949119314
-
A drug transporter for all ages? ABCB1 and the developmental pharmacogenetics of cyclosporine
-
Hesselink DA, van Schaik RH, Nauta J, van Gelder T. A drug transporter for all ages? ABCB1 and the developmental pharmacogenetics of cyclosporine. Pharmacogenomics 2008; 9(6): 783-9.
-
(2008)
Pharmacogenomics
, vol.9
, Issue.6
, pp. 783-789
-
-
Hesselink, D.A.1
van Schaik, R.H.2
Nauta, J.3
van Gelder, T.4
-
136
-
-
35748961114
-
Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges
-
Wilke RA, Lin DW, Roden DM, Watkins PB, Flockhart D, Zineh I, Giacomini KM, Krauss RM. Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat Rev Drug Discov 2007; 6(11): 904-16.
-
(2007)
Nat Rev Drug Discov
, vol.6
, Issue.11
, pp. 904-916
-
-
Wilke, R.A.1
Lin, D.W.2
Roden, D.M.3
Watkins, P.B.4
Flockhart, D.5
Zineh, I.6
Giacomini, K.M.7
Krauss, R.M.8
-
137
-
-
0033574273
-
MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia
-
Abbott GW, Sesti F, Splawski I, Buck ME, Lehmann MH, Timothy KW, Keating MT, Goldstein SA. MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. Cell 1999; 97(2): 175-87.
-
(1999)
Cell
, vol.97
, Issue.2
, pp. 175-187
-
-
Abbott, G.W.1
Sesti, F.2
Splawski, I.3
Buck, M.E.4
Lehmann, M.H.5
Timothy, K.W.6
Keating, M.T.7
Goldstein, S.A.8
-
138
-
-
0028914969
-
A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome
-
Curran ME, Splawski I, Timothy KW, Vincent GM, Green ED, Keating MT. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 1995; 80(5): 795-803.
-
(1995)
Cell
, vol.80
, Issue.5
, pp. 795-803
-
-
Curran, M.E.1
Splawski, I.2
Timothy, K.W.3
Vincent, G.M.4
Green, E.D.5
Keating, M.T.6
-
139
-
-
9044240040
-
Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias
-
Wang Q, Curran ME, Splawski I, Burn TC, Millholland JM, VanRaay TJ, Shen J, Timothy KW, Vincent GM, de Jager T, Schwartz PJ, Toubin JA, Moss AJ, Atkinson DL, Landes GM, Connors TD, Keating MT. Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias. Nat Genet 1996; 12(1): 17-23.
-
(1996)
Nat Genet
, vol.12
, Issue.1
, pp. 17-23
-
-
Wang, Q.1
Curran, M.E.2
Splawski, I.3
Burn, T.C.4
Millholland, J.M.5
VanRaay, T.J.6
Shen, J.7
Timothy, K.W.8
Vincent, G.M.9
de Jager, T.10
Schwartz, P.J.11
Toubin, J.A.12
Moss, A.J.13
Atkinson, D.L.14
Landes, G.M.15
Connors, T.D.16
Keating, M.T.17
-
140
-
-
1442306232
-
Drug-induced prolongation of the QT interval
-
Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med 2004; 350(10): 1013-22.
-
(2004)
N Engl J Med
, vol.350
, Issue.10
, pp. 1013-1022
-
-
Roden, D.M.1
-
141
-
-
0030903368
-
Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients
-
Steen VM, Lovlie R, MacEwan T, McCreadie RG. Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients. Mol Psychiatry 1997; 2(2): 139-45.
-
(1997)
Mol Psychiatry
, vol.2
, Issue.2
, pp. 139-145
-
-
Steen, V.M.1
Lovlie, R.2
MacEwan, T.3
McCreadie, R.G.4
-
142
-
-
0030975438
-
Association of TaqI A polymorphism of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia
-
Chen CH, Wei FC, Koong FJ, Hsiao KJ. Association of TaqI A polymorphism of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia. Biol Psychiatry 1997; 41(7): 827-9.
-
(1997)
Biol Psychiatry
, vol.41
, Issue.7
, pp. 827-829
-
-
Chen, C.H.1
Wei, F.C.2
Koong, F.J.3
Hsiao, K.J.4
-
143
-
-
22344436588
-
Combined analysis of 635 patients confirms an age-related association of the serotonin 2A receptor gene with tardive dyskinesia and specificity for the non-orofacial subtype
-
Lerer B, Segman RH, Tan EC, Basile VS, Cavallaro R, Aschauer HN, Strous R, Chong SA, Heresco-Levy U, Verga M, Scharfetter J, Meltzer HY, Kennedy JL, Macciardi F. Combined analysis of 635 patients confirms an age-related association of the serotonin 2A receptor gene with tardive dyskinesia and specificity for the non-orofacial subtype. Int J Neuropsychopharmacol 2005; 8(3): 411-25.
-
(2005)
Int J Neuropsychopharmacol
, vol.8
, Issue.3
, pp. 411-425
-
-
Lerer, B.1
Segman, R.H.2
Tan, E.C.3
Basile, V.S.4
Cavallaro, R.5
Aschauer, H.N.6
Strous, R.7
Chong, S.A.8
Heresco-Levy, U.9
Verga, M.10
Scharfetter, J.11
Meltzer, H.Y.12
Kennedy, J.L.13
Macciardi, F.14
-
144
-
-
0036371340
-
Association of a polymorphism in the promoter region of the serotonin 5-HT2C receptor gene with tardive dyskinesia in patients with schizophrenia
-
Zhang ZJ, Zhang XB, Sha WW, Reynolds GP. Association of a polymorphism in the promoter region of the serotonin 5-HT2C receptor gene with tardive dyskinesia in patients with schizophrenia. Mol Psychiatry 2002; 7(7): 670-1.
-
(2002)
Mol Psychiatry
, vol.7
, Issue.7
, pp. 670-671
-
-
Zhang, Z.J.1
Zhang, X.B.2
Sha, W.W.3
Reynolds, G.P.4
-
145
-
-
17644394540
-
Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis
-
Templeman LA, Reynolds GP, Arranz B, San L. Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis. Pharmacogenet Genomics 2005; 15(4): 195-200.
-
(2005)
Pharmacogenet Genomics
, vol.15
, Issue.4
, pp. 195-200
-
-
Templeman, L.A.1
Reynolds, G.P.2
Arranz, B.3
San, L.4
-
146
-
-
0026246360
-
substitution of cysteine for arginine 614 in the ryanodine receptor is potentially causative of human malignant hyperthermia
-
Gillard EF, Otsu K, Fujii J, Khanna VK, de Leon S, Derdemezi J, Britt BA, Duff CL, Worton RG, MacLennan DH. substitution of cysteine for arginine 614 in the ryanodine receptor is potentially causative of human malignant hyperthermia. Genomics 1991; 11(3): 751-5.
-
(1991)
Genomics
, vol.11
, Issue.3
, pp. 751-755
-
-
Gillard, E.F.1
Otsu, K.2
Fujii, J.3
Khanna, V.K.4
de Leon, S.5
Derdemezi, J.6
Britt, B.A.7
Duff, C.L.8
Worton, R.G.9
MacLennan, D.H.10
-
147
-
-
0031033922
-
Fc gamma RIIA H/R 131 polymorphism, subclassspecific IgG anti-heparin/platelet factor 4 antibodies and clinical course in patients with heparin-induced thrombocytopenia and thrombosis
-
Arepally G, McKenzie SE, Jiang XM, Poncz M, Cines DB. Fc gamma RIIA H/R 131 polymorphism, subclassspecific IgG anti-heparin/platelet factor 4 antibodies and clinical course in patients with heparin-induced thrombocytopenia and thrombosis. Blood 1997; 89(2): 370-5.
-
(1997)
Blood
, vol.89
, Issue.2
, pp. 370-375
-
-
Arepally, G.1
McKenzie, S.E.2
Jiang, X.M.3
Poncz, M.4
Cines, D.B.5
-
148
-
-
0031687887
-
A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity
-
Weisberg I, Tran P, Christensen B, Sibani S, Rozen R. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 1998; 64(3): 169-72.
-
(1998)
Mol Genet Metab
, vol.64
, Issue.3
, pp. 169-172
-
-
Weisberg, I.1
Tran, P.2
Christensen, B.3
Sibani, S.4
Rozen, R.5
-
149
-
-
0028031814
-
Angiotensin-I-converting enzyme gene polymorphism and susceptibility to cough
-
Furuya K, Yamaguchi E, Hirabayashi T, Itoh A, Hizawa N, Ohnuma N, Kawakami Y. Angiotensin-I-converting enzyme gene polymorphism and susceptibility to cough. Lancet 1994; 343(8893): 354.
-
(1994)
Lancet
, vol.343
, Issue.8893
, pp. 354
-
-
Furuya, K.1
Yamaguchi, E.2
Hirabayashi, T.3
Itoh, A.4
Hizawa, N.5
Ohnuma, N.6
Kawakami, Y.7
-
150
-
-
0034942087
-
The ACE gene polymorphism and cough threshold for capsaicin after cilazapril usage
-
Takahashi T, Yamaguchi E, Furuya K, Kawakami Y. The ACE gene polymorphism and cough threshold for capsaicin after cilazapril usage. Respir Med 2001; 95(2): 130-5.
-
(2001)
Respir Med
, vol.95
, Issue.2
, pp. 130-135
-
-
Takahashi, T.1
Yamaguchi, E.2
Furuya, K.3
Kawakami, Y.4
-
151
-
-
0033858856
-
Bradykinin B(2) receptor gene polymorphism is associated with angiotensin-converting enzyme inhibitor-related cough
-
Mukae S, Aoki S, Itoh S, Iwata T, Ueda H, Katagiri T. Bradykinin B(2) receptor gene polymorphism is associated with angiotensin-converting enzyme inhibitor-related cough. Hypertension 2000; 36(1): 127-31.
-
(2000)
Hypertension
, vol.36
, Issue.1
, pp. 127-131
-
-
Mukae, S.1
Aoki, S.2
Itoh, S.3
Iwata, T.4
Ueda, H.5
Katagiri, T.6
-
152
-
-
0036959461
-
Association of polymorphisms of the reninangiotensin system and bradykinin B2 receptor with ACE-inhibitor-related cough
-
Mukae S, Itoh S, Aoki S, Iwata T, Nishio K, Sato R, Katagiri T. Association of polymorphisms of the reninangiotensin system and bradykinin B2 receptor with ACE-inhibitor-related cough. J Hum Hypertens 2002; 16(12): 857-63.
-
(2002)
J Hum Hypertens
, vol.16
, Issue.12
, pp. 857-863
-
-
Mukae, S.1
Itoh, S.2
Aoki, S.3
Iwata, T.4
Nishio, K.5
Sato, R.6
Katagiri, T.7
-
153
-
-
72849146368
-
Single-nucleotide polymorphism (A118G) in exon 1 of OPRM1 gene causes alteration in downstream signaling by mu-opioid receptor and may contribute to the genetic risk for addiction
-
Deb I, Chakraborty J, Gangopadhyay PK, Choudhury SR, Das S. Single-nucleotide polymorphism (A118G) in exon 1 of OPRM1 gene causes alteration in downstream signaling by mu-opioid receptor and may contribute to the genetic risk for addiction. J Neurochem 2010; 112(2): 486-96.
-
(2010)
J Neurochem
, vol.112
, Issue.2
, pp. 486-496
-
-
Deb, I.1
Chakraborty, J.2
Gangopadhyay, P.K.3
Choudhury, S.R.4
Das, S.5
-
154
-
-
0242464931
-
Ankyrin-B mutation causes type 4 long-QT cardiac arrhythmia and sudden cardiac death
-
Mohler PJ, Schott JJ, Gramolini AO, Dilly KW, Guatimosim S, duBell WH, Song LS, Haurogné K, Kyndt F, Ali ME, Rogers TB, Lederer WJ, Escande D, Le Marec H, Bennett V. Ankyrin-B mutation causes type 4 long-QT cardiac arrhythmia and sudden cardiac death. Nature 2003; 421(6923): 634-9.
-
(2003)
Nature
, vol.421
, Issue.6923
, pp. 634-639
-
-
Mohler, P.J.1
Schott, J.J.2
Gramolini, A.O.3
Dilly, K.W.4
Guatimosim, S.5
duBell, W.H.6
Song, L.S.7
Haurogné, K.8
Kyndt, F.9
Ali, M.E.10
Rogers, T.B.11
Lederer, W.J.12
Escande, D.13
Le Marec, H.14
Bennett, V.15
-
155
-
-
5344223383
-
Ca(V)1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism
-
Splawski I, Timothy KW, Sharpe LM, Decher N, Kumar P, Bloise R, Napolitano C, Schwartz PJ, Joseph RM, Condouris K, Tager-Flusberg H, Priori SG, Sanguinetti MC, KeatingMT. Ca(V)1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. Cell 2004; 1 19(1): 19-31.
-
(2004)
Cell
, vol.119
, Issue.1
, pp. 19-31
-
-
Splawski, I.1
Timothy, K.W.2
Sharpe, L.M.3
Decher, N.4
Kumar, P.5
Bloise, R.6
Napolitano, C.7
Schwartz, P.J.8
Joseph, R.M.9
Condouris, K.10
Tager-Flusberg, H.11
Priori, S.G.12
Sanguinetti, M.C.13
Keating, M.T.14
-
156
-
-
0037161355
-
Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes
-
Yang P, Kanki H, Drolet B, Yang T, Wei J, Viswanathan PC, Hohnloser SH, Shimizu W, Schwartz PJ, Stanton M, Murray KT, Norris K, George AL Jr, Roden DM. Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation 2002; 105(16): 1943-8.
-
(2002)
Circulation
, vol.105
, Issue.16
, pp. 1943-1948
-
-
Yang, P.1
Kanki, H.2
Drolet, B.3
Yang, T.4
Wei, J.5
Viswanathan, P.C.6
Hohnloser, S.H.7
Shimizu, W.8
Schwartz, P.J.9
Stanton, M.10
Murray, K.T.11
Norris, K.12
George, A.L.13
Roden, D.M.14
-
157
-
-
0003425462
-
A common polymorphism associated with antibiotic-induced cardiac arrhythmia
-
Sesti F, Abbott GW, Wei J, Murray KT, Saksena S, Schwartz PJ, Priori SG, Roden DM, George AL Jr, Goldstein SA. A common polymorphism associated with antibiotic-induced cardiac arrhythmia. Proc Natl Acad Sci U S A 2000; 97(19): 10613-8.
-
(2000)
Proc Natl Acad Sci U S A
, vol.97
, Issue.19
, pp. 10613-8
-
-
Sesti, F.1
Abbott, G.W.2
Wei, J.3
Murray, K.T.4
Saksena, S.5
Schwartz, P.J.6
Priori, S.G.7
Roden, D.M.8
George, A.L.9
Goldstein, S.A.10
-
158
-
-
19244371485
-
KVLQT1 C-terminal missense mutation causes a forme fruste long-QT syndrome
-
Donger C, Denjoy I, Berthet M, Neyroud N, Cruaud C, Bennaceur M, Chivoret G, Schwartz K, Coumel P, Guicheney P. KVLQT1 C-terminal missense mutation causes a forme fruste long-QT syndrome. Circulation 1997; 96(9): 2778-81.
-
(1997)
Circulation
, vol.96
, Issue.9
, pp. 2778-2781
-
-
Donger, C.1
Denjoy, I.2
Berthet, M.3
Neyroud, N.4
Cruaud, C.5
Bennaceur, M.6
Chivoret, G.7
Schwartz, K.8
Coumel, P.9
Guicheney, P.10
-
159
-
-
18044396715
-
Pharmacogenomics and acquired long QT syndrome
-
Aerssens J, Paulussen AD. Pharmacogenomics and acquired long QT syndrome. Pharmacogenomics 2005; 6(3): 259-70.
-
(2005)
Pharmacogenomics
, vol.6
, Issue.3
, pp. 259-270
-
-
Aerssens, J.1
Paulussen, A.D.2
-
160
-
-
12844265304
-
An underrecognized challenge in evaluating postmarketing drug safety
-
Roden DM. An underrecognized challenge in evaluating postmarketing drug safety. Circulation 2005; 111(3): 246-8.
-
(2005)
Circulation
, vol.111
, Issue.3
, pp. 246-248
-
-
Roden, D.M.1
-
161
-
-
33646944093
-
Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics?
-
Tarsy D, Baldessarini RJ. Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics? Mov Disord 2006; 21(5): 589-98.
-
(2006)
Mov Disord
, vol.21
, Issue.5
, pp. 589-598
-
-
Tarsy, D.1
Baldessarini, R.J.2
-
162
-
-
33746522294
-
An overview of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study
-
McEvoy JP. An overview of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study. CNS Spectr 2006; 11(7 Suppl 7): 4-8.
-
(2006)
CNS Spectr
, vol.11
, Issue.7 SUPPL.
, pp. 4-8
-
-
McEvoy, J.P.1
-
163
-
-
55449133424
-
Genetic underpinnings of tardive dyskinesia: passing the baton to pharmacogenetics
-
Thelma B, Srivastava V, Tiwari AK. Genetic underpinnings of tardive dyskinesia: passing the baton to pharmacogenetics. Pharmacogenomics 2008; 9(9): 1285-306.
-
(2008)
Pharmacogenomics
, vol.9
, Issue.9
, pp. 1285-1306
-
-
Thelma, B.1
Srivastava, V.2
Tiwari, A.K.3
-
164
-
-
0033046439
-
Genotypic association between the dopamine D3 receptor and tardive dyskinesia in chronic schizophrenia
-
Segman R, Neeman T, Heresco-Levy U, Finkel B, Karagichev L, Schlafman M, Dorevitch A, Yakir A, Lerner A, Shelevoy A, Lerer B. Genotypic association between the dopamine D3 receptor and tardive dyskinesia in chronic schizophrenia. Mol Psychiatry 1999; 4(3): 247-53.
-
(1999)
Mol Psychiatry
, vol.4
, Issue.3
, pp. 247-253
-
-
Segman, R.1
Neeman, T.2
Heresco-Levy, U.3
Finkel, B.4
Karagichev, L.5
Schlafman, M.6
Dorevitch, A.7
Yakir, A.8
Lerner, A.9
Shelevoy, A.10
Lerer, B.11
-
165
-
-
0036342556
-
Association of the Ser9Gly polymorphism in the dopamine D3 receptor gene with tardive dyskinesia in Korean schizophrenics
-
Woo SI, Kim JW, Rha E, Han SH, Hahn KH, Park CS, Sohn JW. Association of the Ser9Gly polymorphism in the dopamine D3 receptor gene with tardive dyskinesia in Korean schizophrenics. Psychiatry Clin Neurosci 2002; 56(4): 469-74.
-
(2002)
Psychiatry Clin Neurosci
, vol.56
, Issue.4
, pp. 469-474
-
-
Woo, S.I.1
Kim, J.W.2
Rha, E.3
Han, S.H.4
Hahn, K.H.5
Park, C.S.6
Sohn, J.W.7
-
166
-
-
0030598907
-
Proposed schizophrenia-related gene polymorphism: expression of the Ser9Gly mutant human dopamine D3 receptor with the Semliki Forest virus system
-
Lundstrom K, Turpin MP. Proposed schizophrenia-related gene polymorphism: expression of the Ser9Gly mutant human dopamine D3 receptor with the Semliki Forest virus system. Biochem Biophys Res Commun 1996; 225(3): 1068-72.
-
(1996)
Biochem Biophys Res Commun
, vol.225
, Issue.3
, pp. 1068-1072
-
-
Lundstrom, K.1
Turpin, M.P.2
-
167
-
-
31344437482
-
Genetic susceptibility to tardive dyskinesia among schizophrenia subjects: IV
-
Srivastava V, Varma PG, Prasad S, Semwal P, Nimgaonkar VL, Lerer B, Deshpande SN, BK T. Genetic susceptibility to tardive dyskinesia among schizophrenia subjects: IV. Role of dopaminergic pathway gene polymorphisms. Pharmacogenet Genomics 2006; 16(2): 111-17.
-
(2006)
Role of dopaminergic pathway gene polymorphisms. Pharmacogenet Genomics
, vol.16
, Issue.2
, pp. 111-117
-
-
Srivastava, V.1
Varma, P.G.2
Prasad, S.3
Semwal, P.4
Nimgaonkar, V.L.5
Lerer, B.6
Deshpande, S.N.7
-
168
-
-
2342562985
-
Cytochrome P-450 2D6*10 C188T polymorphism is associated with antipsychotic-induced persistent tardive dyskinesia in Chinese schizophrenic patients
-
Liou YJ, Wang YC, Bai YM, Lin CC, Yu SC, Liao DL, Lin MW, Chen JY, Lai IC. Cytochrome P-450 2D6*10 C188T polymorphism is associated with antipsychotic-induced persistent tardive dyskinesia in Chinese schizophrenic patients. Neuropsychobiology 2004; 49(4): 167-73.
-
(2004)
Neuropsychobiology
, vol.49
, Issue.4
, pp. 167-173
-
-
Liou, Y.J.1
Wang, Y.C.2
Bai, Y.M.3
Lin, C.C.4
Yu, S.C.5
Liao, D.L.6
Lin, M.W.7
Chen, J.Y.8
Lai, I.C.9
-
169
-
-
42349094914
-
Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions
-
Bakker PR, van Harten PN, van Os J. Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions. Mol Psychiatry 2008; 13(5): 544-56.
-
(2008)
Mol Psychiatry
, vol.13
, Issue.5
, pp. 544-556
-
-
Bakker, P.R.1
van Harten, P.N.2
van Os, J.3
-
170
-
-
36049025851
-
The impact of pharmacogenetics on the development and use of antipsychotic drugs
-
Reynolds GP. The impact of pharmacogenetics on the development and use of antipsychotic drugs. Drug Discov Today 2007; 12(21-22): 953-9.
-
(2007)
Drug Discov Today
, vol.12
, Issue.21-22
, pp. 953-959
-
-
Reynolds, G.P.1
-
171
-
-
33845341401
-
Susceptibility genes for the side effect of antipsychotics on body weight and obesity
-
Chagnon YC. Susceptibility genes for the side effect of antipsychotics on body weight and obesity. Curr Drug Targets 2006; 7(12): 1681-95.
-
(2006)
Curr Drug Targets
, vol.7
, Issue.12
, pp. 1681-1695
-
-
Chagnon, Y.C.1
-
172
-
-
0034103054
-
Identification of polymorphic loci in the promoter region of the serotonin 5-HT2C receptor gene and their association with obesity and type II diabetes
-
Yuan X, Yamada K, Ishiyama-Shigemoto S, Koyama W, Nonaka K. Identification of polymorphic loci in the promoter region of the serotonin 5-HT2C receptor gene and their association with obesity and type II diabetes. Diabetologia 2000; 43(3): 373-6.
-
(2000)
Diabetologia
, vol.43
, Issue.3
, pp. 373-376
-
-
Yuan, X.1
Yamada, K.2
Ishiyama-Shigemoto, S.3
Koyama, W.4
Nonaka, K.5
-
173
-
-
11244270333
-
A genome wide linkage study of obesity as secondary effect of antipsychotics in multigenerational families of eastern Quebec affected by psychoses
-
Chagnon YC, Merette C, Bouchard RH, Emond C, Roy MA, Maziade M. A genome wide linkage study of obesity as secondary effect of antipsychotics in multigenerational families of eastern Quebec affected by psychoses. Mol Psychiatry 2004; 9(12): 1067-74.
-
(2004)
Mol Psychiatry
, vol.9
, Issue.12
, pp. 1067-1074
-
-
Chagnon, Y.C.1
Merette, C.2
Bouchard, R.H.3
Emond, C.4
Roy, M.A.5
Maziade, M.6
-
174
-
-
36749070913
-
Possible association of the pro-melanin-concentrating hormone gene with a greater body mass index as a side effect of the antipsychotic olanzapine
-
Chagnon YC, Bureau A, Gendron D, Bouchard RH, Merette C, Roy MA, Maziade M. Possible association of the pro-melanin-concentrating hormone gene with a greater body mass index as a side effect of the antipsychotic olanzapine. Am J Med Genet B Neuropsychiatr Genet 2007; 144B(8): 1063-9.
-
(2007)
Am J Med Genet B Neuropsychiatr Genet
, vol.144
, Issue.8
, pp. 1063-1069
-
-
Chagnon, Y.C.1
Bureau, A.2
Gendron, D.3
Bouchard, R.H.4
Merette, C.5
Roy, M.A.6
Maziade, M.7
-
175
-
-
1142274548
-
Identification of the gene for vitamin K epoxide reductase
-
Li T, Chang CY, Jin DY, Lin PJ, Khvorova A, Stafford DW. Identification of the gene for vitamin K epoxide reductase. Nature 2004; 427(6974): 541-4.
-
(2004)
Nature
, vol.427
, Issue.6974
, pp. 541-544
-
-
Li, T.1
Chang, C.Y.2
Jin, D.Y.3
Lin, P.J.4
Khvorova, A.5
Stafford, D.W.6
-
176
-
-
21144448879
-
Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose
-
Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, Blough DK, Thummel KE, Veenstra DL, Rettie AE. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005; 352(22): 2285-93.
-
(2005)
N Engl J Med
, vol.352
, Issue.22
, pp. 2285-2293
-
-
Rieder, M.J.1
Reiner, A.P.2
Gage, B.F.3
Nickerson, D.A.4
Eby, C.S.5
McLeod, H.L.6
Blough, D.K.7
Thummel, K.E.8
Veenstra, D.L.9
Rettie, A.E.10
-
177
-
-
44949234553
-
Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans
-
Limdi NA, Arnett DK, Goldstein JA, Beasley TM, McGwin G, Adler BK, Acton RT. Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans. Pharmacogenomics 2008; 9(5): 511-26.
-
(2008)
Pharmacogenomics
, vol.9
, Issue.5
, pp. 511-526
-
-
Limdi, N.A.1
Arnett, D.K.2
Goldstein, J.A.3
Beasley, T.M.4
McGwin, G.5
Adler, B.K.6
Acton, R.T.7
-
178
-
-
34247215617
-
Warfarin response and vitamin K epoxide reductase complex 1 in African Americans and Caucasians
-
Schelleman H, Chen Z, Kealey C, Whitehead AS, Christie J, Price M, Brensinger CM, Newcomb CW, Thorn CF, Samaha FF, Kimmel SE. Warfarin response and vitamin K epoxide reductase complex 1 in African Americans and Caucasians. Clin Pharmacol Ther 2007; 81(5): 742-7.
-
(2007)
Clin Pharmacol Ther
, vol.81
, Issue.5
, pp. 742-747
-
-
Schelleman, H.1
Chen, Z.2
Kealey, C.3
Whitehead, A.S.4
Christie, J.5
Price, M.6
Brensinger, C.M.7
Newcomb, C.W.8
Thorn, C.F.9
Samaha, F.F.10
Kimmel, S.E.11
-
179
-
-
0026323648
-
Familial occurrence of hypersensitivity to phenytoin
-
Gennis MA, Vemuri R, Burns EA, Hill JV, Miller MA, Spielberg SP. Familial occurrence of hypersensitivity to phenytoin. Am J Med 1991; 91(6): 631-4.
-
(1991)
Am J Med
, vol.91
, Issue.6
, pp. 631-634
-
-
Gennis, M.A.1
Vemuri, R.2
Burns, E.A.3
Hill, J.V.4
Miller, M.A.5
Spielberg, S.P.6
-
180
-
-
0034798191
-
Hypersensitivity related to abacavir in two members of a family
-
Peyrieere H, Nicolas J, Siffert M, Demoly P, Hillaire-Buys D, Reynes J. Hypersensitivity related to abacavir in two members of a family. Ann Pharmacother 2001; 35(10): 1291-2.
-
(2001)
Ann Pharmacother
, vol.35
, Issue.10
, pp. 1291-1292
-
-
Peyrieere, H.1
Nicolas, J.2
Siffert, M.3
Demoly, P.4
Hillaire-Buys, D.5
Reynes, J.6
-
181
-
-
0032565185
-
Adverse drug reactions
-
PirmohamedM, Breckenridge AM, Kitteringham NR, Park BK. Adverse drug reactions. BMJ 1998; 316(7140): 1295-8.
-
(1998)
BMJ
, vol.316
, Issue.7140
, pp. 1295-1298
-
-
Pirmohamed, M.1
Breckenridge, A.M.2
Kitteringham, N.R.3
Park, B.K.4
-
182
-
-
0031719374
-
Role of drug disposition in drug hypersensitivity: a chemical, molecular, and clinical perspective
-
Park BK, Pirmohamed M, Kitteringham NR. Role of drug disposition in drug hypersensitivity: a chemical, molecular, and clinical perspective. Chem Res Toxicol 1998; 11(9): 969-88.
-
(1998)
Chem Res Toxicol
, vol.11
, Issue.9
, pp. 969-988
-
-
Park, B.K.1
Pirmohamed, M.2
Kitteringham, N.R.3
-
183
-
-
33645815444
-
Genetic factors in the predisposition to drug-induced hypersensitivity reactions
-
PirmohamedM. Genetic factors in the predisposition to drug-induced hypersensitivity reactions. AAPS J 2006; 8(1): E20-6.
-
(2006)
AAPS J
, vol.8
, Issue.1
-
-
Pirmohamed, M.1
-
184
-
-
0037197044
-
Genetic variations in HLA-B region and hypersensitivity reactions to abacavir
-
Hetherington S, Hughes AR, Mosteller M, Shortino D, Baker KL, Spreen W, Lai E, Davies K, Handley A, Dow DJ, Fling ME, Stocum M, Bowman C, Thurmond LM, Roses AD. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 2002; 359(9312): 1121-2.
-
(2002)
Lancet
, vol.359
, Issue.9312
, pp. 1121-1122
-
-
Hetherington, S.1
Hughes, A.R.2
Mosteller, M.3
Shortino, D.4
Baker, K.L.5
Spreen, W.6
Lai, E.7
Davies, K.8
Handley, A.9
Dow, D.J.10
Fling, M.E.11
Stocum, M.12
Bowman, C.13
Thurmond, L.M.14
Roses, A.D.15
-
185
-
-
0037006623
-
Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir
-
Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, Sayer D, Castley A, Mamotte C, Maxwell D, James I, Christiansen FT. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002; 359(9308): 727-32.186. Chung WH, Hung SI, Hong HS, Hsih MS, Yang LC, Ho HC, Wu JY, Chen YT. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004; 428(6982): 486.
-
(2002)
Lancet
, vol.359
, Issue.9308
, pp. 727-732
-
-
Mallal, S.1
Nolan, D.2
Witt, C.3
Masel, G.4
Martin, A.M.5
Moore, C.6
Sayer, D.7
Castley, A.8
Mamotte, C.9
Maxwell, D.10
James, I.11
Christiansen, F.T.12
-
186
-
-
1842784823
-
Medical genetics: a marker for Stevens-Johnson syndrome
-
Chung WH, Hung SI, Hong HS, Hsih MS, Yang LC, Ho HC, Wu JY, Chen YT. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004; 428(6982): 486.
-
(2004)
Nature
, vol.428
, Issue.6982
, pp. 486
-
-
Chung, W.H.1
Hung, S.I.2
Hong, H.S.3
Hsih, M.S.4
Yang, L.C.5
Ho, H.C.6
Wu, J.Y.7
Chen, Y.T.8
-
187
-
-
33645082244
-
Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions
-
Hung SI, Chung WH, Jee SH, Chen WC, Chang YT, Lee WR, Hu SL, Wu MT, Chen GS, Wong TW, Hsiao PF, Chen WH, Shih HY, Fang WH, Wei CY, Lou YH, Huang YL, Lin JJ, Chen YT. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics 2006; 16(4): 297-306.
-
(2006)
Pharmacogenet Genomics
, vol.16
, Issue.4
, pp. 297-306
-
-
Hung, S.I.1
Chung, W.H.2
Jee, S.H.3
Chen, W.C.4
Chang, Y.T.5
Lee, W.R.6
Hu, S.L.7
Wu, M.T.8
Chen, G.S.9
Wong, T.W.10
Hsiao, P.F.11
Chen, W.H.12
Shih, H.Y.13
Fang, W.H.14
Wei, C.Y.15
Lou, Y.H.16
Huang, Y.L.17
Lin, J.J.18
Chen, Y.T.19
-
188
-
-
0025175183
-
HLA-B38, DR4, DQw3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia
-
Lieberman JA, Yunis J, Egea E, Canoso RT, Kane JM, Yunis EJ. HLA-B38, DR4, DQw3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia. Arch Gen Psychiatry 1990; 47(10): 945-8.
-
(1990)
Arch Gen Psychiatry
, vol.47
, Issue.10
, pp. 945-948
-
-
Lieberman, J.A.1
Yunis, J.2
Egea, E.3
Canoso, R.T.4
Kane, J.M.5
Yunis, E.J.6
-
189
-
-
34748816239
-
Clozapine-induced agranulocytosis in schizophrenic Caucasians: confirming clues for associations with human leukocyte class I and II antigens
-
Dettling M, Cascorbi I, Opgen-Rhein C, Schaub R. Clozapine-induced agranulocytosis in schizophrenic Caucasians: confirming clues for associations with human leukocyte class I and II antigens. Pharmacogenomics J 2007; 7(5): 325-32.
-
(2007)
Pharmacogenomics J
, vol.7
, Issue.5
, pp. 325-332
-
-
Dettling, M.1
Cascorbi, I.2
Opgen-Rhein, C.3
Schaub, R.4
-
190
-
-
12144260460
-
Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts
-
Martin AM, Nolan D, James I, Cameron P, Keller J, Moore C, Phillips E, Christiansen FT, Mallal S. Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts. AIDS 2005; 19(1): 97-9.
-
(2005)
AIDS
, vol.19
, Issue.1
, pp. 97-99
-
-
Martin, A.M.1
Nolan, D.2
James, I.3
Cameron, P.4
Keller, J.5
Moore, C.6
Phillips, E.7
Christiansen, F.T.8
Mallal, S.9
-
191
-
-
33845945094
-
HLA-Cw8 primarily associated with hypersensitivity to nevirapine
-
Gatanaga H, Yazaki H, Tanuma J, Honda M, Genka I, Teruya K, Tachikawa N, Kikuchi Y, Oka S. HLA-Cw8 primarily associated with hypersensitivity to nevirapine. AIDS 2007; 21(2): 264-5.
-
(2007)
AIDS
, vol.21
, Issue.2
, pp. 264-265
-
-
Gatanaga, H.1
Yazaki, H.2
Tanuma, J.3
Honda, M.4
Genka, I.5
Teruya, K.6
Tachikawa, N.7
Kikuchi, Y.8
Oka, S.9
-
192
-
-
77954378516
-
HLA-Cw*04 allele associated with nevirapine-induced rash in HIV-infected Thai patients
-
Likanonsakul S, Rattanatham T, Feangvad S, Uttayamakul S, Prasithsirikul W, Tunthanathip P, Nakayama EE, Shioda T. HLA-Cw*04 allele associated with nevirapine-induced rash in HIV-infected Thai patients. AIDS Res Ther 2009; 6: 22.
-
(2009)
AIDS Res Ther
, vol.6
, pp. 22
-
-
Likanonsakul, S.1
Rattanatham, T.2
Feangvad, S.3
Uttayamakul, S.4
Prasithsirikul, W.5
Tunthanathip, P.6
Nakayama, E.E.7
Shioda, T.8
-
193
-
-
33746767604
-
HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients
-
Littera R, Carcassi C, Masala A, Piano P, Serra P, Ortu F, Corso N, Casula B, La Nasa G, Contu L, Manconi PE. HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients. AIDS 2006; 20(12): 1621-6.
-
(2006)
AIDS
, vol.20
, Issue.12
, pp. 1621-1626
-
-
Littera, R.1
Carcassi, C.2
Masala, A.3
Piano, P.4
Serra, P.5
Ortu, F.6
Corso, N.7
Casula, B.8
La Nasa, G.9
Contu, L.10
Manconi, P.E.11
-
194
-
-
59549096348
-
HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients
-
Chantarangsu S, Mushiroda T, Mahasirimongkol S, Kiertiburanakul S, Sungkanuparph S, Manosuthi W, Tantisiriwat W, Charoenyingwattana A, Sura T, Chantratita W, Nakamura Y. HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients. Pharmacogenet Genomics 2009; 19(2): 139-46.
-
(2009)
Pharmacogenet Genomics
, vol.19
, Issue.2
, pp. 139-146
-
-
Chantarangsu, S.1
Mushiroda, T.2
Mahasirimongkol, S.3
Kiertiburanakul, S.4
Sungkanuparph, S.5
Manosuthi, W.6
Tantisiriwat, W.7
Charoenyingwattana, A.8
Sura, T.9
Chantratita, W.10
Nakamura, Y.11
-
195
-
-
38149108354
-
RegiSCAR study group
-
Lonjou C, Borot N, Sekula P, Ledger N, Thomas L, Halevy S, Naldi L, Bouwes-Bavinck JN, Sidoroff A, de Toma C, Schumacher M, Roujeau JC, Hovnanian A, Mockenhaupt M; RegiSCAR study group. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics 2008; 18(2): 99-107.
-
(2008)
A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics
, vol.18
, Issue.2
, pp. 99-107
-
-
Lonjou, C.1
Borot, N.2
Sekula, P.3
Ledger, N.4
Thomas, L.5
Halevy, S.6
Naldi, L.7
Bouwes-Bavinck, J.N.8
Sidoroff, A.9
de Toma, C.10
Schumacher, M.11
Roujeau, J.C.12
Hovnanian, A.13
Mockenhaupt, M.14
-
196
-
-
0033756344
-
Co-amoxiclav jaundice: clinical and histological features and HLA class II association
-
O'Donohue J, Oien KA, Donaldson P, Underhill J, Clare M, MacSween RN, Mills PR. Co-amoxiclav jaundice: clinical and histological features and HLA class II association. Gut 2000; 47(5): 717-20.
-
(2000)
Gut
, vol.47
, Issue.5
, pp. 717-720
-
-
O'Donohue, J.1
Oien, K.A.2
Donaldson, P.3
Underhill, J.4
Clare, M.5
MacSween, R.N.6
Mills, P.R.7
-
197
-
-
67649859295
-
DILIGEN Study; International SAE Consortium
-
Daly AK, Donaldson PT, Bhatnagar P, Shen Y, Pe'er I, Floratos A, Daly MJ, Goldstein DB, John S, Nelson MR, Graham J, Park BK, Dillon JF, Bernal W, Cordell HJ, Pirmohamed M, Aithal GP, Day CP; DILIGEN Study; International SAE Consortium. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet 2009; 41(7): 816-19.
-
(2009)
HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet
, vol.41
, Issue.7
, pp. 816-819
-
-
Daly, A.K.1
Donaldson, P.T.2
Bhatnagar, P.3
Shen, Y.4
Pe'er, I.5
Floratos, A.6
Daly, M.J.7
Goldstein, D.B.8
John, S.9
Nelson, M.R.10
Graham, J.11
Park, B.K.12
Dillon, J.F.13
Bernal, W.14
Cordell, H.J.15
Pirmohamed, M.16
Aithal, G.P.17
Day, C.P.18
-
198
-
-
0025303320
-
HLA-B27 and agranulocytosis by levamisole
-
Diez RA. HLA-B27 and agranulocytosis by levamisole. Immunol Today 1990; 11(8): 270.
-
(1990)
Immunol Today
, vol.11
, Issue.8
, pp. 270
-
-
Diez, R.A.1
-
199
-
-
70249102418
-
High-resolutionHLA genotyping and severe cutaneous adverse reactions in lamotrigine-treated patients
-
Kazeem GR, Cox C, Aponte J, Messenheimer J, Brazell C, NelsenAC, Nelson MR, Foot E. High-resolutionHLA genotyping and severe cutaneous adverse reactions in lamotrigine-treated patients. Pharmacogenet Genomics 2009; 19(9): 661-5.
-
(2009)
Pharmacogenet Genomics
, vol.19
, Issue.9
, pp. 661-665
-
-
Kazeem, G.R.1
Cox, C.2
Aponte, J.3
Messenheimer, J.4
Brazell, C.5
Nelsen, A.C.6
Nelson, M.R.7
Foot, E.8
-
200
-
-
34248589506
-
Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese
-
Man CB, Kwan P, Baum L, Yu E, Lau KM, Cheng AS, Ng MH. Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia 2007; 48(5): 1015-18.
-
(2007)
Epilepsia
, vol.48
, Issue.5
, pp. 1015-1018
-
-
Man, C.B.1
Kwan, P.2
Baum, L.3
Yu, E.4
Lau, K.M.5
Cheng, A.S.6
Ng, M.H.7
-
201
-
-
0035163638
-
Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir
-
Hetherington S, McGuirk S, Powell G, Cutrell A, Naderer O, Spreen B, Lafon S, Pearce G, Steel H. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther 2001; 23(10): 1603-14.
-
(2001)
Clin Ther
, vol.23
, Issue.10
, pp. 1603-1614
-
-
Hetherington, S.1
McGuirk, S.2
Powell, G.3
Cutrell, A.4
Naderer, O.5
Spreen, B.6
Lafon, S.7
Pearce, G.8
Steel, H.9
-
202
-
-
0036246069
-
Risk factor analysis of hypersensitivity reactions to abacavir
-
Symonds W, Cutrell A, Edwards M, Steel H, Spreen B, Powell G, McGuirk S, Hetherington S. Risk factor analysis of hypersensitivity reactions to abacavir. Clin Ther 2002; 24(4): 565-73.
-
(2002)
Clin Ther
, vol.24
, Issue.4
, pp. 565-573
-
-
Symonds, W.1
Cutrell, A.2
Edwards, M.3
Steel, H.4
Spreen, B.5
Powell, G.6
McGuirk, S.7
Hetherington, S.8
-
203
-
-
12144287198
-
Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant
-
Martin AM, Nolan D, Gaudieri S, Almeida CA, Nolan R, James I, Carvalho F, Phillips E, Christiansen FT, Purcell AW, McCluskey J, Mallal S. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proc Natl Acad Sci U S A 2004; 101(12): 4180-5.
-
(2004)
Proc Natl Acad Sci U S A
, vol.101
, Issue.12
, pp. 4180-4185
-
-
Martin, A.M.1
Nolan, D.2
Gaudieri, S.3
Almeida, C.A.4
Nolan, R.5
James, I.6
Carvalho, F.7
Phillips, E.8
Christiansen, F.T.9
Purcell, A.W.10
McCluskey, J.11
Mallal, S.12
-
204
-
-
34250022859
-
Immune responses to abacavir in antigen-presenting cells from hypersensitive patients
-
Martin AM, Almeida CA, Cameron P, Purcell AW, Nolan D, James I, McCluskey J, Phillips E, Landay A, Mallal S. Immune responses to abacavir in antigen-presenting cells from hypersensitive patients. AIDS 2007; 21(10): 1233-44.
-
(2007)
AIDS
, vol.21
, Issue.10
, pp. 1233-1244
-
-
Martin, A.M.1
Almeida, C.A.2
Cameron, P.3
Purcell, A.W.4
Nolan, D.5
James, I.6
McCluskey, J.7
Phillips, E.8
Landay, A.9
Mallal, S.10
-
205
-
-
20644470742
-
Clinical and immunogenetic correlates of abacavir hypersensitivity
-
Phillips EJ, Wong GA, Kaul R, Shahabi K, Nolan DA, Knowles SR, Martin AM, Mallal SA, Shear NH. Clinical and immunogenetic correlates of abacavir hypersensitivity. AIDS 2005; 19(9): 979-81.
-
(2005)
AIDS
, vol.19
, Issue.9
, pp. 979-981
-
-
Phillips, E.J.1
Wong, G.A.2
Kaul, R.3
Shahabi, K.4
Nolan, D.A.5
Knowles, S.R.6
Martin, A.M.7
Mallal, S.A.8
Shear, N.H.9
-
206
-
-
33745295856
-
Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study
-
Rauch A, Nolan D, Martin A, McKinnon E, Almeida C, Mallal S. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study. Clin Infect Dis 2006; 43(1): 99-102.
-
(2006)
Clin Infect Dis
, vol.43
, Issue.1
, pp. 99-102
-
-
Rauch, A.1
Nolan, D.2
Martin, A.3
McKinnon, E.4
Almeida, C.5
Mallal, S.6
-
207
-
-
34247636623
-
Prospective screening for human leukocyte antigen-B*5701 avoids abacavir hypersensitivity reaction in the ethnically mixed French HIV population
-
Zucman D, Truchis P, Majerholc C, Stegman S, Caillat-Zucman S. Prospective screening for human leukocyte antigen-B*5701 avoids abacavir hypersensitivity reaction in the ethnically mixed French HIV population. J Acquir Immune Defic Syndr 2007; 45(1): 1-3.
-
(2007)
J Acquir Immune Defic Syndr
, vol.45
, Issue.1
, pp. 1-3
-
-
Zucman, D.1
Truchis, P.2
Majerholc, C.3
Stegman, S.4
Caillat-Zucman, S.5
-
208
-
-
3042634326
-
Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity
-
Hughes DA, Vilar FJ, Ward CC, Alfirevic A, Park BK, Pirmohamed M. Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity. Pharmacogenetics 2004; 14(6): 335-42.
-
(2004)
Pharmacogenetics
, vol.14
, Issue.6
, pp. 335-342
-
-
Hughes, D.A.1
Vilar, F.J.2
Ward, C.C.3
Alfirevic, A.4
Park, B.K.5
Pirmohamed, M.6
-
209
-
-
38949196447
-
PREDICT-1 Study Team
-
Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, Jägel-Guedes E, Rugina S, Kozyrev O, Cid JF, Hay P, Nolan D, Hughes S, Hughes A, Ryan S, Fitch N, Thorborn D, Benbow A; PREDICT-1 Study Team. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008; 358(6): 568-79.
-
(2008)
HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med
, vol.358
, Issue.6
, pp. 568-579
-
-
Mallal, S.1
Phillips, E.2
Carosi, G.3
Molina, J.M.4
Workman, C.5
Tomazic, J.6
Jägel-Guedes, E.7
Rugina, S.8
Kozyrev, O.9
Cid, J.F.10
Hay, P.11
Nolan, D.12
Hughes, S.13
Hughes, A.14
Ryan, S.15
Fitch, N.16
Thorborn, D.17
Benbow, A.18
-
210
-
-
12144291646
-
CNA30027 Study Team; CNA30032 Study Team
-
Hughes AR, Mosteller M, Bansal AT, Davies K, Haneline SA, Lai EH, Nangle K, Scott T, Spreen WR, Warren LL, Roses AD; CNA30027 Study Team; CNA30032 Study Team. Association of genetic variations in HLAB region with hypersensitivity to abacavir in some, but not all, populations. Pharmacogenomics 2004; 5(2): 203-11.
-
(2004)
Association of genetic variations in HLAB region with hypersensitivity to abacavir in some, but not all, populations. Pharmacogenomics
, vol.5
, Issue.2
, pp. 203-211
-
-
Hughes, A.R.1
Mosteller, M.2
Bansal, A.T.3
Davies, K.4
Haneline, S.A.5
Lai, E.H.6
Nangle, K.7
Scott, T.8
Spreen, W.R.9
Warren, L.L.10
Roses, A.D.11
-
211
-
-
42549131532
-
Study of Hypersensitivity to Abacavir and Pharmacogenetic Evaluation Study Team
-
Saag M, Balu R, Phillips E, Brachman P, Martorell C, Burman W, Stancil B, Mosteller M, Brothers C, Wannamaker P, Hughes A, Sutherland-Phillips D, Mallal S, Shaefer M; Study of Hypersensitivity to Abacavir and Pharmacogenetic Evaluation Study Team. High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. Clin Infect Dis 2008; 46(7): 1111-18.
-
(2008)
High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. Clin Infect Dis
, vol.46
, Issue.7
, pp. 1111-1118
-
-
Saag, M.1
Balu, R.2
Phillips, E.3
Brachman, P.4
Martorell, C.5
Burman, W.6
Stancil, B.7
Mosteller, M.8
Brothers, C.9
Wannamaker, P.10
Hughes, A.11
Sutherland-Phillips, D.12
Mallal, S.13
Shaefer, M.14
-
212
-
-
84886183600
-
DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents - AWorking Group of the Office of AIDS Research Advisory Council (OARAC)
-
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. 1 December 2009
-
DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents - AWorking Group of the Office of AIDS Research Advisory Council (OARAC). Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. 1 December 2009. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.
-
-
-
-
213
-
-
42449120613
-
Pharmacogenetic information derived from analysis of HLA alleles
-
Gatanaga H, Honda H, Oka S. Pharmacogenetic information derived from analysis of HLA alleles. Pharmacogenomics 2008; 9(2): 207-14.
-
(2008)
Pharmacogenomics
, vol.9
, Issue.2
, pp. 207-214
-
-
Gatanaga, H.1
Honda, H.2
Oka, S.3
-
214
-
-
0028793442
-
Anticonvulsant hypersensitivity syndrome
-
Vittorio CC, Muglia JJ. Anticonvulsant hypersensitivity syndrome. Arch Intern Med 1995; 155(21): 2285-90.
-
(1995)
Arch Intern Med
, vol.155
, Issue.21
, pp. 2285-2290
-
-
Vittorio, C.C.1
Muglia, J.J.2
-
215
-
-
0033606436
-
Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study
-
Rzany B, Correia O, Kelly JP, Naldi L, Auquier A, Stern R. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Study Group of the International Case Control Study on Severe Cutaneous Adverse Reactions. Lancet 1999; 353(9171): 2 190-4.
-
(1999)
Study Group of the International Case Control Study on Severe Cutaneous Adverse Reactions. Lancet
, vol.353
, Issue.9171
-
-
Rzany, B.1
Correia, O.2
Kelly, J.P.3
Naldi, L.4
Auquier, A.5
Stern, R.6
-
216
-
-
57449118501
-
Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population
-
Locharernkul C, Loplumlert J, Limotai C, Korkij W, Desudchit T, Tongkobpetch S, Kangwanshiratada O, Hirankarn N, Suphapeetiporn K, Shotelersuk V. Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population. Epilepsia 2008; 49(12): 2087-91.
-
(2008)
Epilepsia
, vol.49
, Issue.12
, pp. 2087-2091
-
-
Locharernkul, C.1
Loplumlert, J.2
Limotai, C.3
Korkij, W.4
Desudchit, T.5
Tongkobpetch, S.6
Kangwanshiratada, O.7
Hirankarn, N.8
Suphapeetiporn, K.9
Shotelersuk, V.10
-
217
-
-
33645065133
-
Serious carbamazepine-induced hypersensitivity reactions associated with the HSP70 gene cluster
-
Alfirevic A, Mills T, Harrington P, Pinel T, Sherwood J, Jawaid A, Smith JC, March RE, Barratt BJ, Chadwick DW, Park KB, Pirmohamed M. Serious carbamazepine-induced hypersensitivity reactions associated with the HSP70 gene cluster. Pharmacogenet Genomics 2006; 16(4): 287-96.
-
(2006)
Pharmacogenet Genomics
, vol.16
, Issue.4
, pp. 287-296
-
-
Alfirevic, A.1
Mills, T.2
Harrington, P.3
Pinel, T.4
Sherwood, J.5
Jawaid, A.6
Smith, J.C.7
March, R.E.8
Barratt, B.J.9
Chadwick, D.W.10
Park, K.B.11
Pirmohamed, M.12
-
218
-
-
33748987340
-
HLA-B locus inCaucasian patients with carbamazepine hypersensitivity
-
Alfirevic A, JorgensenAL, Williamson PR, ChadwickDW, ParkBK, PirmohamedM.HLA-B locus inCaucasian patients with carbamazepine hypersensitivity. Pharmacogenomics 2006; 7(6): 813-8.
-
(2006)
Pharmacogenomics
, vol.7
, Issue.6
, pp. 813-818
-
-
Alfirevic, A.1
Jorgensen, A.L.2
Williamson, P.R.3
Chadwick, D.W.4
Park, B.K.5
Pirmohamed, M.6
-
219
-
-
61549115662
-
JSAR research group
-
Kaniwa N, Saito Y, Aihara M, Matsunaga K, TohkinM, KuroseK, Sawada J, Furuya H, TakahashiY, Muramatsu M, Kinoshita S, Abe M, Ikeda H, Kashiwagi M, Song Y, Ueta M, Sotozono C, Ikezawa Z, Hasegawa R; JSAR research group. HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics 2008; 9(11): 1617-22.
-
(2008)
HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics
, vol.9
, Issue.11
, pp. 1617-1622
-
-
Kaniwa, N.1
Saito, Y.2
Aihara, M.3
Matsunaga, K.4
Tohkin, M.5
Kurose, K.6
Sawada, J.7
Furuya, H.8
Takahashi, Y.9
Muramatsu, M.10
Kinoshita, S.11
Abe, M.12
Ikeda, H.13
Kashiwagi, M.14
Song, Y.15
Ueta, M.16
Sotozono, C.17
Ikezawa, Z.18
Hasegawa, R.19
-
220
-
-
0025809328
-
A population-based study of Stevens-Johnson syndrome
-
Strom BL, Carson JL, Halpern AC, Schinnar R, Snyder ES, Shaw M, Tilson HH, Joseph M, Dai WS, Chen D, Stern RS, Bergman U, Stolley PD. A population-based study of Stevens-Johnson syndrome. Incidence and antecedent drug exposures. Arch Dermatol 1991; 127(6): 831-8.
-
(1991)
Incidence and antecedent drug exposures. Arch Dermatol
, vol.127
, Issue.6
, pp. 831-838
-
-
Strom, B.L.1
Carson, J.L.2
Halpern, A.C.3
Schinnar, R.4
Snyder, E.S.5
Shaw, M.6
Tilson, H.H.7
Joseph, M.8
Dai, W.S.9
Chen, D.10
Stern, R.S.11
Bergman, U.12
Stolley, P.D.13
-
221
-
-
37649006062
-
Investigation into the multidimensional genetic basis of drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis
-
Pirmohamed M, Arbuckle JB, Bowman CE, Brunner M, Burns DK, Delrieu O, Dix LP, Twomey JA, Stern RS. Investigation into the multidimensional genetic basis of drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics 2007; 8(12): 1661-91.
-
(2007)
Pharmacogenomics
, vol.8
, Issue.12
, pp. 1661-1691
-
-
Pirmohamed, M.1
Arbuckle, J.B.2
Bowman, C.E.3
Brunner, M.4
Burns, D.K.5
Delrieu, O.6
Dix, L.P.7
Twomey, J.A.8
Stern, R.S.9
-
223
-
-
77956550478
-
International Serious Adverse Events Consortium
-
International Serious Adverse Events Consortium. http://www.saeconsortium.org/.
-
-
-
-
224
-
-
0037374498
-
The price of innovation: new estimates of drug development costs
-
DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ 2003; 22(2): 151-85.
-
(2003)
J Health Econ
, vol.22
, Issue.2
, pp. 151-185
-
-
DiMasi, J.A.1
Hansen, R.W.2
Grabowski, H.G.3
-
225
-
-
4344684441
-
Pharmacogenetics and drug development: the path to safer and more effective drugs
-
Roses AD. Pharmacogenetics and drug development: the path to safer and more effective drugs. Nat Rev Genet 2004; 5(9): 645-56.
-
(2004)
Nat Rev Genet
, vol.5
, Issue.9
, pp. 645-656
-
-
Roses, A.D.1
-
226
-
-
0035056821
-
Pharmacogenetic application in drug development and clinical trials
-
Shi MM, Bleavins MR, de la Iglesia FA. Pharmacogenetic application in drug development and clinical trials. Drug Metab Dispos 2001; 29(4 Pt 2): 591-5.
-
(2001)
Drug Metab Dispos
, vol.29
, Issue.4
, pp. 591-595
-
-
Shi, M.M.1
Bleavins, M.R.2
de la Iglesia, F.A.3
-
227
-
-
53249118974
-
Pharmacogenetics in drug discovery and development: a translational perspective
-
Roses AD. Pharmacogenetics in drug discovery and development: a translational perspective. Nat Rev Drug Discov 2008; 7(10): 807-17.
-
(2008)
Nat Rev Drug Discov
, vol.7
, Issue.10
, pp. 807-817
-
-
Roses, A.D.1
-
228
-
-
45749146622
-
PhRMA White Paper on ADME pharmacogenomics
-
Williams JA, Andersson T, Andersson TB, Blanchard R, Behm MO, Cohen N, Edeki T, Franc M, Hillgren KM, Johnson KJ, Katz DA, Milton MN, Murray BP, Polli JW, Ricci D, Shipley LA, Vangala S, Wrighton SA. PhRMA White Paper on ADME pharmacogenomics. J Clin Pharmacol 2008; 48(7): 849-89.
-
(2008)
J Clin Pharmacol
, vol.48
, Issue.7
, pp. 849-889
-
-
Williams, J.A.1
Andersson, T.2
Andersson, T.B.3
Blanchard, R.4
Behm, M.O.5
Cohen, N.6
Edeki, T.7
Franc, M.8
Hillgren, K.M.9
Johnson, K.J.10
Katz, D.A.11
Milton, M.N.12
Murray, B.P.13
Polli, J.W.14
Ricci, D.15
Shipley, L.A.16
Vangala, S.17
Wrighton, S.A.18
-
229
-
-
33751103939
-
Adding pharmacogenetics information to drug labels: lessons learned
-
Haga SB, Thummel KE, Burke W. Adding pharmacogenetics information to drug labels: lessons learned. Pharmacogenet Genomics 2006; 16(12): 847-54.
-
(2006)
Pharmacogenet Genomics
, vol.16
, Issue.12
, pp. 847-854
-
-
Haga, S.B.1
Thummel, K.E.2
Burke, W.3
-
230
-
-
52149112915
-
Pharmacogenetics of hypersensitivity to abacavir: from PGx hypothesis to confirmation to clinical utility
-
Hughes AR, Spreen WR, Mosteller M, Warren LL, Lai EH, Brothers CH, Nelsen AJ, Hughes S, Thorborn DE, Stancil B, Hetherington SV, Burns DK, Roses AD. Pharmacogenetics of hypersensitivity to abacavir: from PGx hypothesis to confirmation to clinical utility. Pharmacogenomics J 2008; 8(6): 365-74.
-
(2008)
Pharmacogenomics J
, vol.8
, Issue.6
, pp. 365-374
-
-
Hughes, A.R.1
Spreen, W.R.2
Mosteller, M.3
Warren, L.L.4
Lai, E.H.5
Brothers, C.H.6
Nelsen, A.J.7
Hughes, S.8
Thorborn, D.E.9
Stancil, B.10
Hetherington, S.V.11
Burns, D.K.12
Roses, A.D.13
-
231
-
-
69049114189
-
Pharmacogenomics of adverse drug reactions: practical applications and perspectives
-
Becquemont L. Pharmacogenomics of adverse drug reactions: practical applications and perspectives. Pharmacogenomics 2009; 10(6): 961-9.
-
(2009)
Pharmacogenomics
, vol.10
, Issue.6
, pp. 961-969
-
-
Becquemont, L.1
-
232
-
-
0005248386
-
US Food and Drug Administration
-
FDA Approves Updated Warfarin (Coumadin) Prescribing Information
-
US Food and Drug Administration. FDA Approves Updated Warfarin (Coumadin) Prescribing Information. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108967.htm.
-
-
-
-
233
-
-
69349094274
-
FDA narrows drug label usage
-
Dolgin E. FDA narrows drug label usage. Nature 2009; 460(7259): 1069.
-
(2009)
Nature
, vol.460
, Issue.7259
, pp. 1069
-
-
Dolgin, E.1
-
234
-
-
67650642313
-
Clinically available pharmacogenomics tests
-
Flockhart DA, Skaar T, Berlin DS, Klein TE, Nguyen AT. Clinically available pharmacogenomics tests. Clin Pharmacol Ther 2009; 86(1): 109-13.
-
(2009)
Clin Pharmacol Ther
, vol.86
, Issue.1
, pp. 109-113
-
-
Flockhart, D.A.1
Skaar, T.2
Berlin, D.S.3
Klein, T.E.4
Nguyen, A.T.5
-
235
-
-
77956249134
-
Evaluation of Genomic Applications in Practice and Prevention (EGAPP)
-
Evaluation of Genomic Applications in Practice and Prevention (EGAPP). http://www.egappreviews. org/default.htm.
-
-
-
-
237
-
-
59849108152
-
EGAPP Working Group
-
Teutsch SM, Bradley LA, Palomaki GE, Haddow JE, Piper M, Calonge N, Dotson WD, Douglas MP, Berg AO; EGAPP Working Group. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group. Genet Med 2009; 11(1): 3-14.
-
(2009)
The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group. Genet Med
, vol.11
, Issue.1
, pp. 3-14
-
-
Teutsch, S.M.1
Bradley, L.A.2
Palomaki, G.E.3
Haddow, J.E.4
Piper, M.5
Calonge, N.6
Dotson, W.D.7
Douglas, M.P.8
Berg, A.O.9
-
238
-
-
37349093041
-
Recommendations from the EGAPPWorking Group: testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors
-
Recommendations from the EGAPPWorking Group: testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors. Genet Med 2007; 9(12): 819-25.
-
(2007)
Genet Med
, vol.9
, Issue.12
, pp. 819-252
-
-
-
239
-
-
59849117793
-
Recommendations from the EGAPPWorking Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan?
-
Recommendations from the EGAPPWorking Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? Genet Med 2009; 11(1): 15-20.
-
(2009)
Genet Med
, vol.11
, Issue.1
, pp. 15-20
-
-
-
241
-
-
29544447266
-
TheAmpliChip CYP450 genotyping test: Integrating a newclinical tool
-
de Leon J, SusceMT, Murray-Carmichael E. TheAmpliChip CYP450 genotyping test: Integrating a newclinical tool. Mol Diagn Ther 2006; 10(3): 135-51.
-
(2006)
Mol Diagn Ther
, vol.10
, Issue.3
, pp. 135-151
-
-
de Leon, J.1
Susce, M.T.2
Murray-Carmichael, E.3
-
242
-
-
0005248386
-
US Food and Drug Administration
-
Table of Valid Genomic Biomarkers in the Context of Approved Drug Labels
-
US Food and Drug Administration. Table of Valid Genomic Biomarkers in the Context of Approved Drug Labels. http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm.
-
-
-
-
243
-
-
77954243597
-
Pharmacogenomics: role in medicines approval and clinical use
-
Novelli G, Borgiani P, Ciccacci C, Di Daniele N, Sirugo G, Papaluca Amati M. Pharmacogenomics: role in medicines approval and clinical use. Public Health Genomics 2010; 13(5): 284-91.
-
(2010)
Public Health Genomics
, vol.13
, Issue.5
, pp. 284-291
-
-
Novelli, G.1
Borgiani, P.2
Ciccacci, C.3
Di Daniele, N.4
Sirugo, G.5
Papaluca Amati, M.6
-
244
-
-
77952671414
-
Association of the manganese superoxide dismutase gene Ala-9Val polymorphism with clinical phenotypes and tardive dyskinesia in schizophrenic patients
-
Liu H, Wang C, Chen PH, Zhang BS, Zheng YL, Zhang CX, et al. Association of the manganese superoxide dismutase gene Ala-9Val polymorphism with clinical phenotypes and tardive dyskinesia in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34(4): 692-6.
-
(2010)
Prog Neuropsychopharmacol Biol Psychiatry
, vol.34
, Issue.4
, pp. 692-696
-
-
Liu, H.1
Wang, C.2
Chen, P.H.3
Zhang, B.S.4
Zheng, Y.L.5
Zhang, C.X.6
|